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The purpose of this review is to provide a critical appraisal of the literature on Glutamine (Gln) supplementation in various
conditions or illnesses that aﬀect children, from neonates to adolescents. First, a general overview of the proposed mechanisms for
thebeneﬁcialeﬀectsofGlnisprovided,andsubsequentlyclinicalstudiesarediscussed.Despitesafety,studiesareconﬂicting,partly
due to diﬀerent eﬀects of enteral and parenteral Gln supplementation. Further insuﬃcient evidence is available on the beneﬁts
of Gln supplementation in pediatric patients. This includes premature infants, infants with gastrointestinal disease, children
with Crohn’s disease, short bowel syndrome, malnutrition/diarrhea, cancer, severe burns/trauma, Duchenne muscular dystrophy,
sickle cell anemia, cystic ﬁbrosis, and type 1 diabetes. Moreover, methodological issues have been noted in some studies. Further
mechanisticdataisneededalongwithlargerandomizedcontrolledtrialsinselectpopulationsofsickchildren,whomayeventually
beneﬁt from supplemental Gln.
1.Introduction
Glutamine (Gln) is the most abundant amino acid in the
muscle and plasma of humans [1]. Although Gln is a nones-
sential neutral amino acid, it is necessary for optimal growth
of mammalian cells in tissue culture [2] and has important
physiological functions. Apart from providing nitrogen for
protein synthesis, Gln is a precursor for nucleic acids,
nucleotides [3], hexosamines [4], the nitric oxide precursor-
arginine (Arg) [5], and the major antioxidant-glutathione
[4, 6]. Gln is also an important oxidative fuel for rapidly
proliferating cells such as those of the gastrointestinal tract
[7] and immune system [3], reticulocytes [8], ﬁbroblasts
[9], and so on. It plays a central role in nitrogen transport
between tissues [10], speciﬁcally from muscle to gut, kidney,
and liver. In addition to its role as a gluconeogenic substrate
in the liver, kidney [11], and intestine [12], Gln is involved in
therenalhandlingofammonia,servingasaregulatorofacid-
base homeostasis [13]. Present data also indicate that Gln
functions as a signalling molecule [14], particularly under
catabolic conditions.
Traditionally Gln is considered a nonessential amino
acid, because it is synthesized by most tissue (skeletal
muscle being the main producer and storage site) [15].
Gln synthetase catalyzes the terminal step in Gln de novo
synthesis and is a key enzyme in Gln metabolism [16, 17].
In mammals, Gln synthetase expression is regulated by
transcriptional and posttranscriptional mechanisms, that is,
increasing Gln synthetase mRNA in response to stress (e.g.,
glucocorticoids) and regulation of Gln synthetase protein
turnover in response to its product (Gln concentrations)
[18]. The importance of Gln at the whole body level is
highlighted by the report of severe brain malformation
resulting in multiorgan failure and neonatal death in 2 unre-
lated newborns with congenital Gln synthetase deﬁciency, in
whom Gln was largely absent in plasma, urine, and cerebral
spinal ﬂuid [19].
Under normal conditions, Gln is released into circu-
lation for consumption by other tissue, whereas during
catabolic stress the production of Gln may be insuﬃcient
to meet the increased requirements by the gut, immune
system/inﬂammatory cells, liver, and kidneys. Demands are2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
partly met by skeletal muscle proteolysis and release of large
amounts of Gln to maintain normal concentrations in the
plasma, resulting in depletion of Gln stores. Based on this
abundant evidence, Lacey and Wilmore [10] suggested that
Gln may become a conditionally essential amino acid for the
critically ill.
In paediatrics, several researchers have studied the eﬃ-
cacy of supplemental Gln in premature infants of low birth
weight (LBW), who are highly stressed and have low energy
andproteinreserves[20].Similartoprematureneonates,Gln
supplementation may also be beneﬁcial for other childhood
conditions including gastrointestinal disease, malnutrition,
cancer, severe burns/trauma as well as chronic diseases of
childhood. However, less data is available on the eﬀects of
supplemental Gln in older infants and children with various
diseases.
In addition to being sick and highly stressed, children
are also in the process of growth and development. Hence,
speciﬁc research on the role of Gln in pediatric patients is
necessary. The main purpose of this manuscript is to provide
a critical review of the literature on Gln supplementation
in various conditions/illnesses that aﬀect children (from
neonates to adolescents). First the proposed mechanisms of
Gln action are reviewed in a general context, followed by a
detailed description and critique of the clinical research on
Gln supplementation in children.
1.1. Glutamine Mechanisms of Action. W h i l ei ti sw e l le s t a b -
lished that Gln is a protein precursor as well as a major fuel
and nucleotide substrate for rapidly proliferating cells (e.g.,
gut and immune system) [3, 7], additional mechanistic data
has emerged to explain the apparent beneﬁts of Gln. Gln can
regulate the expression of many genes related to metabolism,
signal transduction, cell defense, and repair and can activate
intracellular signaling pathways [14]. In brief, Gln seems
to aﬀect antioxidant capacity, tissue protection, immune,
and metabolic function [21] as well as protein synthesis
anddegradation[14](Figure 1).Thepostulatedmechanisms
remain speculative and are by no means mutually exclusive,
since Gln can provoke a number of diﬀerent eﬀects that
interact with one another.
1.2. Antioxidant Capacity
1.2.1. Glutathione. Gln is a precursor of the glutamate (Glu),
for glutathione (L-γ-glutamyl-L-cysteinyl-glycine) synthesis,
an important antioxidant in many cell types [22]. Glu-
tathione is present in the cell in reduced (GSH) and oxidized
(GSSG) forms. The ratio of reduced-to-oxidized glutathione
is the major regulator of the cellular redox potential that
determines the antioxidant capacity of the cell [14, 22, 23].
The eﬀectiveness of glutathione protection in individual
tissue depends on the tissue concentration of glutathione as
wellasthecapacityofthetissuetoimportGSHandtoexport
GSSG [24].
In vivo experiments in rats demonstrate that adminis-
tration of Gln before ischemia/reperfusion injury or surgical
manipulation can enhance GSH concentrations and provide
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Figure 1: Schematic representation of the mechanism of glutamine
action.
protectionagainstoxidativestressinvarioustissues(e.g.,car-
diac, intestinal, and lung) [25, 26]. Further, the eﬀectiveness
of Gln in preventing liver damage in neonatal sepsis appears
to be mediated via glutathione synthesis [27]. In humans,
GlnsupplementationcanattenuateGSHdepletioninskeletal
muscle following surgical trauma [28].
During critical illness, muscle concentrations of GSH
decrease and a change in the redox status occurs, indicative
of an elevated GSSG [24]. Moreover, there is a correlation
between the concentrations of Gln and GSH [24]. Shifting
the GSH/GSSG redox toward oxidizing conditions acti-
vates several signaling pathways, such as c-Jun N-terminal
kinase (JNK), apoptosis signal-regulated kinase-1 (ASK-1),
mitogen-activated protein kinase (MAPK), and the tran-
scription factor nuclear factor-kappaB (NF-κB: a stimulator
of the synthesis of proinﬂammatory cytokines and adhesion
molecules) [22, 23, 29]. Evidence also implicates oxidative
stress as a potential regulator of NF-κB transactivation by
MAPKs (in particular extracellular signal-regulated kinase
1/2 (ERK1/2) and p38) [30]w h i c hc o u l dl e a dt oi n c r e a s e d
proteolysis in muscle [31]. Moreover, the cellular redox
status seems to be related to the degree of muscle protein
degradation [32, 33]. Likewise, there is signiﬁcant literature
on the role of inﬂammatory cytokines (interleukin-1, -6,
tumour necrosis factor-alpha (TNF-α)) and muscle wasting
[34].
Gln metabolism via entry into the citric acid cycle may
allow the activation of malic enzyme which will result
in an increase in NADPH [15] and subsequently increase
the GSH/GSSG ratio [14]. Administration of Gln leads to
an increased ratio of GSH/GSSG and reduces the activity
of redox sensitive kinases subsequently preventing NF-κB
activation and thus inhibiting the inﬂammatory response
[23].
Experiments from our group in the mdx mouse model
of muscular dystrophy (a condition associated with severe
muscle wasting) showed that in vivo Gln administration
can reduce GSSG in dystrophic skeletal muscle, hence,
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with decreased activation of MAPK (ERK1/2) pathway [35].
Similar eﬀects were observed in muscle of control mice;
however, the magnitude was less [35]. Thus, in muscle tissue,
Gln might aﬀect the cellular redox state involving MAPK
pathway.
1.3. Tissue Protection
1.3.1. Heat Shock Protein (HSP). The HSPs serve as molec-
ular chaperones that appear to repair denatured/injured
proteins or promote their degradation following irreparable
injury. Gln has cell-protective eﬀects, as a potent enhancer
of the expression of HSP25, HSP70, HSP72, and heme-
oxygenase-1 in cell culture [36], in multiple organs of both
stressed and unstressed animal models [37], as well as in
humans [38, 39]. However, Gln depletion during the stress
response can impair the expression of the major inducible
HSP (HSP70), as shown in human lymphocytes [40]. And
recent evidence suggests that HSP70 expression is required
for Gln’s protection against tissue injury and for attenuation
of NF-κB activation and proinﬂammatory cytokine release
[41].
In rats, preoperative administration of Gln induces
HSP70 expression and attenuates the inﬂammatory response
by regulating nitric oxide synthase (NOS) activity in heart,
lung, and liver [42]. Gln is a well-known precursor for
Arg [5], which can increase nitric oxide formation as a
result of enhanced NOS activity [6]. However, in various
models of human intestinal cells, Gln does not further
increase nitric oxide production or inducible NOS mRNA
following proinﬂammatory cytokine stimulation [43]. Thus,
Gln’s eﬀects on NOS activity might be tissue- or condition-
speciﬁc.
The survival-promoting eﬀects of HSP70 can also be
attributed in part to the suppression of apoptosis, since
reduced HSP expression in Gln-deprived cells together with
their impaired antioxidant capacity may make them more
susceptible to apoptosis [29].
1.3.2. Apoptosis. Gln starvation has been shown to induce
apoptosis in intestinal epithelial cells [44] and also ren-
ders human monocytic cells more susceptible to apoptosis
induced by Fas ligand, heat shock, or TNF-α stimulation
[45]. In HeLa cells, Gln might also suppress ASK-1 and
JNK/stress-activated protein kinase (SAPK) activation by
Fas ligand [46]. The eﬀect of Gln in delaying spontaneous
apoptosis in neutrophils may be mediated by the antioxidant
eﬀects of glutathione [47]. Furthermore, Gln may protect
activated T cells from apoptosis, partially by upregulating
glutathione and Bcl-2 expression and inhibiting Fas [48].
1.3.3. Intestinal Barrier Function. As an important fuel for
intestinal tissue and gut-associated lymphoid tissue, Gln
may contribute to gut barrier function [49]. Experimental
data from neonatal animal models also support the ben-
eﬁcial eﬀects of Gln on gastrointestinal development and
function [50–59]. Gln is also involved in the biosynthesis
of hexosamines which are important for maintaining gut
wall integrity via surface mucin and glycoprotein-forming
intracellular tight junctions and thus may protect against
bacterial translocation [4, 60].
1.4. Immune Function. As a major fuel for immune cells,
Gln is known to modulate immune function. More recently,
Gln has also been shown to have anti-inﬂammatory eﬀects,
modulating cytokine production, both in vitro [36, 61–63]
and in vivo [41, 51, 64], possibly through decreased NF-κB
activation [41, 62], a major transcription factor regulating
immune and inﬂammatory responses. In neonatal mice and
rats with experimental NEC, Gln reduces intestinal injury
[54, 55], via mechanisms inhibiting inﬂammatory cytokine
release [54].
Gln’s anti-inﬂammatory eﬀects may also be related to
enhanced HSP expression [36, 41]. The induction of HSP
response can attenuate proinﬂammatory cytokine release,
which in turn depends on the cellular redox potential and
consequently is regulated by the intracellular GSH/GSSG
ratio [14] (as previously described).
1.5.TissueMetabolicFunction. Glncanpreservetissue-meta-
bolic function in stress states. For instance, Gln enhan-
ces myocardial tissue-metabolic function after ischemia/
reperfusion injury in rats [26]. Gln can also enhance ATP
levels in oxidant stressed endothelial cells [65].
1.5.1. Glucose Metabolism. While Gln plays an important
role in gluconeogenesis [11, 12, 66], evidence also suggests
that Gln can improve insulin sensitivity and glucose disposal
in patients suﬀering from critical illness [21, 67], a condition
frequently associated with insulin resistance and subsequent
hyperglycemia. Gln also plays a role as a signaling molecule
in amino acid- and glucose-stimulated insulin secretion
[68]. Interestingly in rats with diet-induced obesity, Gln
supplementation induces insulin resistance in adipose tissue
and reduces adipose mass, consequently attenuating insulin
resistance and activation of JNK and inhibitory kappaB
kinase subunit beta in liver and muscle, thus improving
insulin signaling [69]. These data suggest that Gln can bene-
ﬁcially inﬂuence insulin-dependent glucose metabolism.
1.6. Protein Synthesis and Degradation. Gln appears to
regulate protein turnover in cultured rat skeletal myotubes,
stimulating protein synthesis in stressed myotubes while
inhibiting protein degradation in long-lived proteins. This
may be related to the increase in HSP70 [70] .T h e r ei sa l s o
abundant literature to suggest that amino acids aﬀectprotein
turnover via the mammalian target of rapamycin (mTOR)
pathway [71, 72].
1.6.1. Protein Synthesis. Amino acids, particularly branched
chain amino acids, for example, leucine (Leu) stimulate
skeletal muscle protein synthesis via the activation of mTOR
whichinturnactivatesp70ribosomalS6kinase(p70S6K)and
dephosphorylates eukaryotic initiation factor 4E-binding
protein 1 (4E-BP 1), stimulating translation and protein
synthesis [71, 72]. Gln can induce growth and maturation
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an increase in the mRNAs-encoding contractile proteins and
metabolic enzymes via the activation of protein kinase A
a n dm T O R[ 73]. However, the action of Gln seems to be
cell-type speciﬁc. For instance, in C2C12 myogenic cells,
Gln and Leu have opposite eﬀects on the mTOR pathway
[74]. Whereas Leu activates this pathway, Gln inhibits it by
decreasing the phosphorylation states of mTOR (on serine
(Ser)2448), p70S6K,a n d4 E - B P 1 ,w i t hn oe ﬀect on protein
synthesis [74].
1.6.2. Protein Degradation. The major proteolytic pathways
in organs such as the liver, muscle, and intestine include
the autophagic/lysosomal (cathepsins), the calcium activated
(calpains), and the ATP-ubiquitin-proteosome pathway [14,
34]. The proteosome system (26S) is a highly selective prote-
olytic pathway [71]. In visceral tissues (e.g., liver), autophagy
is, however, the major proteolytic pathway and the only
pathway known to be regulated by plasma amino acids (in
liver and skeletal muscle) [71, 72]. In autophagic proteolysis,
several amino acids have direct regulatory potential, possibly
via a plasma membrane amino acid receptor/sensor and
subsequent intracellular signaling [71].
Another line of evidence suggests that amino acids
activate mTOR pathway which in turn suppresses protein
breakdown by the autophagy/lysosomal pathway [71, 72].
Aminoacidscanalsocontrolautophagiclysosomalproteoly-
sis by inhibiting MAPK (ERK1/2) phosphorylation [75]. Gln
may cause its antiproteolytic eﬀect through osmotic swelling
[76], involving p38 MAPK pathway [77]. An increase in
cellular hydration acts as an anabolic signal, whereas cell
shrinkage is catabolic, and there is a close relation in the
regulation of cell volume, Gln, and protein catabolism [23].
On the other hand in the human gut, enteral Gln may
attenuate ubiquitin-dependent proteolysis as demonstrated
bydecreasedubiquitinmRNA,whereasmRNAsencodingfor
cathepsins or calpains were not aﬀected [78]. Furthermore,
in lung and muscle, Gln can also regulate its own production
through a posttranscriptional mechanism in which Gln
regulates Gln synthetase protein degradation [16, 17, 79],
by facilitating its degradation by the 26S proteosome [18].
Thus,thepresenceofGlncouldhaveaprotein-sparingeﬀect,
sparing amino acids for protein accretion [80–82].
1.7. Glutamine in the Neonatal Period. Gln is the predomi-
nant amino acid supplied to the fetus through the placenta
and is speciﬁcally suited for its rapid development [83, 84].
While normally present in the enteral diet, Gln has been
excluded from parenteral nutrition (PN) because of low
solubility and instability in solution. In the ﬁrst weeks of life,
however, premature infants receive most of their nutrients
from PN which is Gln-free [85]. The sudden cessation of
Gln supply from the mother to premature infants, who
are already stressed and undergoing rapid growth, may
be detrimental [86]. Whereas plasma Gln concentrations
normally increase during the ﬁrst days of life in newborn
infants breastfed ad libitum [87], selective amino acid
deﬁciencies have been reported in neonates suﬀering from
acute illness, including reductions in serum Gln and Arg in
infants who have necrotizing enterocolitis (NEC) that may
predispose them to the illness [88]. It has been suggested
that in catabolic conditions premature infants are not able
to synthesize suﬃcient Gln to meet demands, and in these
conditions Gln may become a conditionally essential amino
acid [10].
1.8. Glutamine in Breast Milk. In addition to providing an
ideal nutritional composition for the neonate, breast milk
contains speciﬁc nutrients such as Gln that may inﬂuence
gastrointestinal development and can modulate immune,
metabolic, and inﬂammatory responses [89]. Deprivation
of dietary or endogenously synthesized Gln results in a
breakdown in the intestinal epithelium of artiﬁcially reared
neonatal rats, whereas Gln supplementation may help to
maintain intestinal integrity [59].
In extremely low birth weight (ELBW) infants, the
beneﬁcial eﬀects of breast milk ingested in the neonatal
intensive care unit (NICU) on developmental outcomes at
18 months of age [90] persist at 30 months [91]. While
PN is Gln-free, Agostoni et al. [92]r e p o r t e dl o w e rf r e e
Gln concentrations in standard infant formulas compared
to breast milk collected from 40 healthy lactating mothers
after delivery of term infants at age 1 month. And similar
to previous reports [93], they observed that glutamic acid
and Gln accounted for most of the free amino acids in
breast milk [92]. Moreover, heat sterilization of infant
formulas can further lower the concentrations of Gln by
more than 60% [94]. Thus, suggesting that enrichment
of infant formulas with nonprotein nitrogen components
(particularly Gln and glutamic acid) could be beneﬁcial. The
same group followed 16 healthy exclusively breastfeeding
mothers after delivery of term infants and showed that the
concentrations of free glutamic acid and Gln increased by
2.5 and 20 fold, respectively, with progressing lactation,
representing >50% of total free amino acids by 3 months
[95]. To assess the potential inﬂuence of gestational age
and duration of lactation, Jochum et al. [96]m e a s u r e d
the content of free and protein-bound Gln in transitional
and mature breast milk of 40 healthy mothers after term
and preterm delivery. While the time of delivery had no
inﬂuence on the free Gln or total Gln concentration, free Gln
concentrations increased during maturation of lactogenesis,
similar to previous reports [95, 97, 98]. In contrast, total Gln
and protein-bound Gln concentrations decreased with the
duration of lactation, and this correlated with the decrease in
totalproteinconcentrationinmaturebreastmilk[96].These
data highlight the need to better deﬁne the role of Gln in
the neonatal period and the possible beneﬁt of supplemental
Gln.
2.MaterialsandMethods
The following sections describe the clinical studies that
examined the eﬀects of parenteral and enteral Gln supple-
mentation in premature neonates as well as older infants
and children with various diseases. The search methods for
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(1966–June 2011). The database was searched using the
search term: “glutamine.” The search output was limited
with the search ﬁlter for ages: all children 0–18 years. There
were no language restrictions. References in previous reviews
and studies were examined also. The title and abstract of all
studies identiﬁed by the above search strategy were screened,
and the full text for all potentially relevant studies published
in English was obtained. The full text of any potentially
relevant studies was assessed by the ﬁrst author. Studies that
included only adult participants were excluded. The same
author extracted data from the published studies.
3. Results andDiscussion
3.1. Parenteral Glutamine Supplementation in
Premature Neonates
3.1.1. Clinical Outcomes. The ﬁrst evidence to suggest that
parenteral Gln appears safe and may be considered a con-
ditionally essential amino acid in premature infants was put
forth more than a decade ago by Lacey et al. [99]( Table 1).
Although eﬃcacy was not demonstrated in the entire cohort
ofverylowbirthweight(VLBW)infants(N = 44),subgroup
analysis in the infants with birth weight <800g (n = 24)
showed that those supplemented with Gln (20% of amino
acids) had fewer d on PN (13 versus 21d, P<0.05),
required less time to full feeds (8 versus 14d, P<0.05), and
needed less time on a ventilator (38 versus 47d, P<0.05)
compared to standard isonitrogenous isocaloric PN. The
positive results, however, were based on subgroup analyses,
followup of recruited infants was incomplete, and intention-
to-treat analysis was not performed. Thompson et al. [100]
further demonstrated that parenteral Gln may reduce the
time to establish full feeds and appears to be well tolerated
and safe in a group of 35 ill ELBW neonates randomized to
standard PN supplemented with Gln (16% of amino acids)
or standard PN containing an isocaloric isonitrogenous
amino acid solution. The primary outcome (median d to
achieve full enteral nutrition (EN)) was signiﬁcantly shorter
in the Gln group (Gln: 13d versus control: 21d, P<0.05),
whereas other clinical outcomes (growth, infection, number
of episodes of sepsis, NEC, or age at discharge) did not
diﬀer. The study, however, did not achieve the calculated
sample size of 120 infants. It is also not clear whether groups
diﬀered with respect to enteral feeding with either breast
milk or preterm formula (that was started on d-3 of life).
Although sample sizes were small, both trials were generally
of good quality and provided evidence for improved feeding
t o l e r a n c ew i t hp a r e n t e r a lG l n .
More recently, Li et al. [101] have examined the eﬀects of
PN supplemented with alanyl-Gln dipeptide for more than
2 weeks in 53 premature infants of LBW. Gln-supplemented
infants requiredfewerd onPN (24.8 versus30.8d, P<0.05),
had shorter hospital stays (32.1 versus 38.6d, P<0.05) and
fewer episodes of hospital-acquired infections (0.96 versus
1.84 times, P<0.0001) compared to infants who received
routine PN. They also regained birth weight sooner (8.1
versus 10.4d, P<0.05), whereas there were no diﬀerences
between groups for body weight or head circumference.
The results should be interpreted with caution due to
limitations in the methodology. It was not clear whether
treatment allocation was randomized or whether care givers
or assessors were blinded to the intervention. In addition,
followup of recruited infants was incomplete. Although 68
infants were enrolled, 15 infants were excluded from the
analysis because of insuﬃcient time on PN (<2 weeks) and
intention-to-treat analysis was not performed.
Poindexter et al. [102] performed the largest multicentre
trial to determine whether early PN supplemented with Gln
reduces the risk of mortality or late onset sepsis in ELBW
infants. Within 72h after birth, 1433 infants were randomly
assigned to receive either a standard IV amino acid solution
(control)oranisonitrogenousaminoacidsolutionwith20%
Gln, whenever they received PN, up to 120d of age, death, or
discharge from hospital. Safety was also assessed in a subset
of 141 ELBW infants by measuring plasma concentrations of
amino acids and ammonia after infants had received study
PN (2.3 ± 1.0g/kg/d amino acids) for approximately 10d
[103]. While parenteral Gln supplement increased plasma
Gln concentrations with no apparent biochemical risk in
ELBW infants, Gln did not reduce the incidence of death
or late onset sepsis (Gln: 51% versus control: 48%; RR
[95% CI]: 1.07 [0.97–1.17]). There were no diﬀerences
between groups in the number of episodes of late onset
sepsis, NEC, d on ventilator, length of hospital stay, d to
ﬁrst and full enteral feeds, feeding intolerance, or growth.
Moreover, infants who received Gln required more d of
PN support. Although apparently safe in ELBW infants, the
authorsconcludedthatparenteralGlnsupplementationdoes
not reduce mortality or late onset sepsis, and its routine use
cannot be recommended. The lack of signiﬁcant eﬀect could
be explained by a number of factors. Firstly, the primary
outcome (death or late onset sepsis) could be inﬂuenced by
other factors during the clinical course. In addition, as in
previous studies [99–101] that used isonitrogenous controls
(to ensure the speciﬁc eﬀect of Gln), the overall amino
acid intake may have been inadequate in the Gln group, as
a consequence of the substitution of 20% of the standard
amino acids with Gln. Speciﬁcally, in order to make the sup-
plements isonitrogenous, amino acids (including essential)
were removed from the Gln-containing supplement, which
could exacerbate speciﬁc amino acid deﬁciencies (especially
if the PN period is prolonged). And although plasma amino
acidsweresimilar between groups, comparing plasma amino
acid concentrations may not represent a valid marker for
nutrient equivalence, since plasma amino acids may not
reﬂect whole body amino acid concentrations or tissue
concentrations.Furthermore, becauseinfantsin both groups
did not receive the targeted amino acid intake of 3.0g/kg/d
until 10d of age and most had also received small volumes
of EN, the delivery of a suﬃcient dose of Gln may have been
inconsistent.Moreover,diﬀerencesinenteralintake(formula
or breast milk) may limit comparability of nutrient intakes
between study groups.
More recently, a double blind randomized trial in VLBW
infants found no diﬀerence in mortality with parenteral
Gln supplementation (0.3g/kg/d) versus control [104]. The
trial, however, was not powered to study rare outcomes6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1: Glutamine-supplemented parenteral nutrition in premature neonates.
Reference Subjects Design Gln Control Outcomes Results
Lacey et al.
1996 [99]
44 VLBW
premature
neonates age <4d
receiving PN for
<3d; birth wt:
530–1250g; GA
<32wk
Randomized
double blind
Isonitrogenous
isocaloric PN
supplemented
with Gln
(15–25% of AA
mix) for 14 ±6d
(n = 22)
Standard PN for
16 ±10d
(n = 22)
Time to full EN, d
on PN, d on
ventilator, LOS,
other clinical
outcomes and
safety monitored
throughout
hospitalisation
No diﬀerences for
entire cohort; birth wt
<800g subgroup had
fewer d on PN, fewer d
to full feeds, fewer d on
ventilator, higher
lymphocyte count, no
diﬀerence in NICU
LOS, safe
Des Robert
et al. 2002
[105]
13 LBW age <3d
receiving
exclusive PN;
birth wt:
820–1650g; GA:
28–30wk
Randomized
double blind
Gln-
supplemented
0.5g/kg/d
exclusive PN
started on d3 of
life for 24h, AA
intake at
1.5g/kg/d by d3
(n = 6)
Isonitrogenous
Gln-free AA
(Prim` ene)
supplemented
exclusive PN
started on d3 of
life for 24h, AA
intake at
1.5g/kg/d by d3
(n = 7)
Whole body
protein
metabolism/Leu
kinetics (IV
infusions of
NaH13CO3 and
L-[1–13C]Leu)
on d4 of life
during
continuous PN
(fed state)
Decreased rates of Leu
release from protein
breakdown and Leu
oxidation, decreased
rates of nonoxidative
Leu disposal (an index
of whole-body protein
synthesis), safe
Thompson
et al. 2003
[100]
35 ELBW ill
premature
neonates age
<1d; birth wt:
<1000g
Randomized
double blind
Standard
isonitrogenous
isocaloric PN
supplemented
with 16% of AA
as Gln started on
d1 of life, AA
intake started at
1.0g/kg/d to
≤3.0g/kg/d
(n = 17)
Standard PN
started on d1 of
life, AA intake
started at
1.0g/kg/d to
≤3.0g/kg/d
(n = 18)
(1) Feeding
tolerance;
(2) growth, age at
discharge,
infection,
number of
episodes of
culture-positive
sepsis or NEC,
metabolic
tolerance and
safety monitored
until expected
date of delivery,
discharge or
death (whichever
came ﬁrst)
( 1 )F e w e rdt or e a c h
full EN; (2) no
diﬀerences in gastric
residuals, d to regain
birth wt, wt gain,
infection, total white
cell count, episodes of
low white cell count,
number of episodes of
culture-positive sepsis
or NEC, age at
discharge or death, well
tolerated and safe
Poindexter
et al. 2004∗
[102]
1433 ELBW
(≤72h after
birth); birth wt:
401–1000g; GA:
26 ± 2wk
Multicentre-
randomized
double blind
Isonitrogenous
study AA solution
with 20% of AA
as Gln in PN until
120d of age,
death, or
discharge
(whichever came
ﬁrst), AA intake
≤3–3.5g/kg/d
(n = 721)
Standard AA
solution without
Gln
(TrophAmine) in
PN until 120d of
age, death or
discharge
(whichever came
ﬁrst), AA intake
≤3–3.5g/kg/d
(n = 712)
(1) Death or late
onset sepsis;
( 2 )n u m b e ro f
episodes of late
onset sepsis,
N E C ,do n
ventilator, LOS in
hospital,
tolerance of
enteral feeds,
feeding
intolerance,
growth, d of PN,
safety
(1) No diﬀerences in
death or late onset
sepsis (culture after
72h of age), (2) no
diﬀerences in number
of episodes of late onset
s e p s i s ,N E C ,do n
ventilator, LOS in
hospital, d to ﬁrst/full
enteral feeds,
incidence/number of
episodes of feeding
intolerance, d to reach
1500g or wt at 36wk
postmenstrual age,
increased d of PN, well
tolerated and safeJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 7
Table 1: Continued.
Reference Subjects Design Gln Control Outcomes Results
Poindexter
et al. 2003∗
[103]
141 ELBW (≤72h
after birth); birth
wt: 401–1000g;
GA: 26 ±2wk
Multicentre-
randomized
double blind
Isonitrogenous
study AA solution
with 20% of AA
as Gln in PN for
∼10d, AA intake
≤3–3.5g/kg/d
(n = 72)
Standard AA
solution without
Gln
(TrophAmine) in
PN for ∼10d, AA
intake
≤3–3.5g/kg/d
(n = 69)
Safety as assessed
by plasma
concentrations of
AA and ammonia
after infants had
received study PN
(2.3 ±1.0g/kg/d
AA) for ∼10d
Increased plasma Gln
(Gln group only) with
no apparent
biochemical risk,
increased plasma
essential AA (both
groups) whereas Phe
and Tyr decreased with
greater decrease in Tyr
(Gln group), no change
in plasma ammonia
Kalhan et al.
2005 [80]
20 LBW clinically
stable (24–48h
after birth); birth
wt: 694–1590g;
GA ≤32wk
Randomized
double blind
Isonitrogenous
AA mixture
supplemented
with Gln
0.6g/kg/d in PN
for 3–5d, AA
intake
∼3.0g/kg/d
(n = 10)
AA mixture
without Gln in
PN for 3–5d, AA
intake
∼3.0g/kg/d
(n = 10)
Whole body
protein and Gln
kinetics (IV
infusions of
[2H5]Phe, L-[1–
13C,15N]Leu,
[15N2]urea,
L-[5–15N]Gln)
on d6 or d7 of life
while receiving
AA mixture
continuously
after 3–5d
Lower endogenous
rates of appearance of
Phe and Leu N (indices
of proteolysis), lower
Gln de novo synthesis,
no diﬀerences in rate of
appearance of Leu C,
urea turnover or
plasma AA
concentrations
Li et al.
2007 [101]
53 LBW
premature infants
(48–72h after
birth); birth wt:
<2000g; GA
<37wk
Prospective
intervention
Isonitrogenous
AA solution with
20% of AA
content as
Alanyl-Gln
dipeptide in PN
until >2wk,AA
intake started at
0.5–1.0g/kg/d to
≤3.0g/kg/d
(n = 28)
Routine PN until
>2wk, AA intake
started at
0.5–1.0g/kg/d to
≤3.0g/kg/d
(n = 25)
Growth,
biochemical
indices, feeding
tolerance, and
infective episodes
throughout
hospitalization
Fewer d to regain birth
wt, no diﬀerences in wt
or head
circumferences, fewer d
on PN, fewer episodes
of hospital-acquired
infection, shorter LOS
in hospital, safe
Wang et al.
2010 [104]
30 VLBW;
median age
(interquartile
range) (d):
2.5(1.0-2.0) (Gln)
and 2.2(1.0-2.0)
(control); birth
wt: <1500g; PN
for ≥7d; mean
GA (wk) ±SD:
31.3 ±1.5( G l n )
and 30.5 ±1.8
(control)
Multicentre-
randomized
double blind
6% pediatric AA
compound
injection, average
AA dosage
1.7g/kg/d with
Gln 0.3g/kg/d,
PN decreased
when EN
increased and PN
withheld when
>70% of
recommended
intake from EN
(n = 13)
6% pediatric AA
compound
injection, average
AA dosage
2.0g/kg/d, PN
decreased when
EN increased and
PN withheld
when >70% of
recommended
intake from EN
(n = 15)
(1) Mortality and
changes in
hepatic function
(bile acid, ALT,
AST, total
bilirubin, direct
bilirubin,
prealbumin,
albumin), (2)
time to full EN
(d), episodes of
gastric residual,
total duration of
PN (d), wt gain
(g/d), head
circumference
(cm), LOS, d on
ventilator
(1) Decreased AST and
direct bilirubin, no
diﬀerences in bile acid,
ALT, total bilirubin,
prealbumin, or
albumin, (2) no
diﬀerences in time to
full EN, episodes of
gastric residual, total
duration of PN, wt
gain, head
circumference, LOS or
do nv e n t i l a t o r
VLBW: very low birth weight; PN: parenteral nutrition; wt: weight; GA: gestational age; AA: amino acid; EN: enteral nutrition; LOS: length of stay; NICU:
neonatal intensive care unit; LBW: low birth weight; IV: intravenous; ELBW: extremely low birth weight; NEC: necrotizing enterocolitis; AST: aspartate
aminotransferase; ALT: alanine aminotransferase.
∗Originating from the same cohort.8 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
(such as mortality) or multiple endpoints. Furthermore,
no deaths occurred and only 28/30 infants randomized
completed the study and thus analysis was not by intention
to treat. Interestingly, hepatic function improved as assessed
by serum aspartate aminotransferase and direct bilirubin,
which both decreased after PN in the Gln-supplemented
group (P<0.05). It should be noted, however, that no
diﬀerences were observed for other measures of hepatic
function (bile acid, alanine aminotransferase, total bilirubin,
prealbumin, or albumin) or other secondary outcomes (time
to full EN, episodes of gastric residuals, total duration of PN,
weight gain, head circumference, length of stay, or days on
ventilator).
3.1.2. Protein Metabolism. Two small randomized con-
trolled trials in LBW infants examined the eﬀects of Gln-
supplemented PN on whole body protein metabolism using
primed continuous IV infusions of essential amino acid
tracers [80, 105]( Table 1) .D e sR o b e r te ta l .[ 105] studied
13 LBW neonates on postnatal d-3, while they received
exclusive PN that was supplemented with Gln (0.5g/kg/d)
or an isonitrogenous Gln-free amino acid solution for 24h.
Compared to an isonitrogenous amino acid supplement,
Gln decreased the rate of plasma Leu appearance, Leu
release from protein breakdown (an index of whole body
proteolysis; −16%, P<0.05), and rate of Leu oxidation
(−35%, P<0.05). There was also, however, a decrease in
nonoxidative Leu disposal (an index of whole body protein
synthesis; −20%, P<0.05), and, thus, net Leu balance
(protein balance) did not diﬀer between groups. Plasma Gln
concentrations were higher in Gln versus control, whereas
plasma ammonia did not diﬀer. Although parenteral Gln
failed to enhance estimates of protein synthesis, Gln may
preserve body protein as it suppressed Leu oxidation and
protein breakdown in LBW infants. In addition to the small
sample size, the failure to enhance protein synthesis may
have also been due to insuﬃcient amino acid availability
since whole body protein kinetics were assessed on d-4 of life
(when amino acid intake was 2g/kg/d in both groups) before
infants received an optimal amino acid intake of 3g/kg/d
[106].
Kalhan et al. [80] examined the eﬀect of 0.6g/kg/d
Gln-supplemented PN for 3–5d on whole body protein
and Gln kinetics in a carefully selected population of 20
clinically stable LBW infants, between d-1 and -2 after birth.
Compared to an isonitrogenous control, Gln-supplemented
PN resulted in signiﬁcantly lower rates of appearance of
phenylalanine (Phe) and Leu nitrogen and a nonsigniﬁcant
decrease in the rate of appearance of Leu carbon. Gln also
suppressed the endogenous rate of Gln synthesis. There was
no signiﬁcant diﬀerence in urea turnover between the 2
groups. The results suggest that parenteral Gln supplemen-
tation at 0.6g/kg/d decreases whole body protein breakdown
andGlndenovosynthesisinclinicallystableLBWinfantsand
may be beneﬁcial in selected populations of LBW infants.
The carefully selected population of clinically stable infants
limits the application of the results to other groups of
premature neonates. Moreover, the use of a higher dose of
Gln makes comparisons with other studies diﬃcult.
Interestingly, the same group demonstrated that the
suppression of proteolysis and protein oxidation in response
to an acute increase in parenteral amino acids (without
Gln) was not evident when the amino acid infusion was
continued for a prolonged period in both acutely ill [81]a n d
clinically stable LBW infants [82]. The only exception was
when amino acids were supplemented with Gln, whereby
a prolonged infusion resulted in a sustained inhibition of
whole body proteolysis and reduced Gln de novo synthesis.
Taken together with previous studies [80, 105], Gln supple-
mentation may have a protein-sparing eﬀect in premature
infants decreasing whole body protein breakdown and Gln
denovosynthesisthereby“sparing”theincreasedaminoacids
for protein synthesis.
3.2. Enteral Glutamine Supplementation in
Premature Neonates
3.2.1. Clinical Outcomes. Neu et al. [107]c o n d u c t e da
double-blind randomized trial to test whether enteral Gln
supplementation for VLBW infants decreases morbidity
(Table 2). Sixty-eight premature neonates were assigned to
a Gln-supplemented premature formula or a nonsupple-
mented standard premature formula between postnatal d-
3 to d-30. The Gln supplemented group initially received a
dose of 0.08g/kg/d Gln which was increased to a maximum
of 0.31g/kg/d Gln by d-13. The Gln group had better
tolerancetoenteralfeedings(fewer%ofdwithnooralintake
in Gln: 8.8% versus controls: 23.8%, P<0.01). Episodes
of hospital-acquired sepsis were 4/35 and 10/33 in Gln and
control group, respectively. Moreover, when controlling for
birth weight, the estimated odds of developing sepsis was
3.8 times higher for control versus Gln (95% CI: 1.01–
14.18). Analysis of T cell subsets showed a blunting of the
rise in HLA-DR+ and CD16/CD56 in the Gln group. There
were, however, no signiﬁcant diﬀerences between groups
for cases of NEC, growth, or length of stay. Whereas the
plasma concentrations of alanine (Ala), glycine (Gly), Ser,
threonine (Thr), Phe, and total nonessential amino acids
were lower in the Gln-supplemented infants after 2-week
supplementation, there were no diﬀerences between groups
for plasma concentrations of Gln, Glu, or ammonia [108].
The authors speculated that the lower plasma amino acid
concentrations in infants fed Gln were the result of enhanced
uptake of these amino acids for gluconeogenesis and provide
evidence of reduced tissue catabolism. A secondary analysis
of the initial trial also provided evidence for decreased
hospital costs [109]. While the control used is comparable
to routine clinical practice, the study design cannot ensure
the speciﬁc eﬀect of Gln as the diﬀerences between feeding
groups might result from higher intakes of nitrogen or
energy with Gln supplementation. The authors, however,
chosenottouseathirdgroupwithanisonitrogenouscontrol
due to recruitment constraints. Although the trial was small,
these initial results provided evidence for better tolerance
to enteral feedings and lower sepsis rates in VLBW infants
receiving enteral Gln supplementation.
Barbosa et al. [110]c o n d u c t e dar a n d o m i z e dc o n t r o l l e d
pilot study to evaluate the tolerance and clinical impact ofJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 9
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n
s
u
p
p
l
e
m
e
n
t
e
d
)
a
n
d
P
N
N
o
d
i
ﬀ
e
r
e
n
c
e
s
i
n
o
v
e
r
a
l
l
r
a
t
e
o
f
a
p
p
e
a
r
a
n
c
e
o
f
L
e
u
a
n
d
G
l
n
,
n
o
d
i
ﬀ
e
r
e
n
c
e
s
i
n
L
e
u
a
n
d
G
l
n
r
e
l
e
a
s
e
f
r
o
m
p
r
o
t
e
i
n
b
r
e
a
k
d
o
w
n
,
n
o
d
i
ﬀ
e
r
e
n
c
e
s
i
n
G
l
n
d
e
n
o
v
o
s
y
n
t
h
e
s
i
s
o
r
p
l
a
s
m
a
G
l
n
c
o
n
c
e
n
t
r
a
t
i
o
n
s
D
a
l
l
a
s
e
t
a
l
.
1
9
9
8
∗
[
1
0
9
]
6
8
V
L
B
W
a
g
e
<
3
d
r
e
c
e
i
v
i
n
g
P
N
;
b
i
r
t
h
w
t
:
5
0
0
–
1
2
5
0
g
;
G
A
:
2
4
–
3
2
w
k
R
a
n
d
o
m
i
z
e
d
d
o
u
b
l
e
-
b
l
i
n
d
F
r
o
m
d
3
t
o
d
3
0
o
f
l
i
f
e
r
e
c
e
i
v
e
d
p
r
e
m
a
t
u
r
e
f
o
r
m
u
l
a
(
S
i
m
i
l
a
c
S
p
e
c
i
a
l
C
a
r
e
G
r
o
u
p
)
s
u
p
p
l
e
m
e
n
t
e
d
w
i
t
h
G
l
n
a
t
0
.
0
8
g
/
k
g
/
d
o
n
d
3
a
n
d
r
e
a
c
h
e
d
0
.
3
1
g
/
k
g
/
d
b
y
d
1
3
,
P
N
A
A
s
t
a
r
t
e
d
a
t
0
.
5
g
/
k
g
/
d
o
n
d
3
u
n
t
i
l
3
g
/
k
g
/
d
b
y
d
8
(
n
=
3
5
)
F
r
o
m
d
3
t
o
d
3
0
o
f
l
i
f
e
r
e
c
e
i
v
e
d
p
r
e
m
a
t
u
r
e
f
o
r
m
u
l
a
(
S
i
m
i
l
a
c
S
p
e
c
i
a
l
C
a
r
e
G
r
o
u
p
)
a
l
o
n
e
,
P
N
A
A
s
t
a
r
t
e
d
a
t
0
.
5
g
/
k
g
/
d
o
n
d
3
u
n
t
i
l
3
g
/
k
g
/
d
b
y
d
8
(
n
=
3
3
)
H
o
s
p
i
t
a
l
c
o
s
t
s
a
n
a
l
y
s
e
d
b
y
l
o
g
-
r
a
n
k
t
e
s
t
s
a
n
d
K
a
p
l
a
n
-
M
e
i
e
r
p
l
o
t
s
R
e
d
u
c
e
d
m
e
d
i
a
n
c
o
s
t
s
f
o
r
h
o
s
p
i
t
a
l
i
s
a
t
i
o
n
,
r
a
d
i
o
l
o
g
y
,
p
h
a
r
m
a
c
y
,
l
a
b
o
r
a
t
o
r
y
,
a
n
d
N
I
C
U
,
r
e
d
u
c
e
d
m
e
d
i
a
n
n
u
m
b
e
r
o
f
u
t
i
l
i
z
a
t
i
o
n
u
n
i
t
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a
b
l
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2
:
C
o
n
t
i
n
u
e
d
.
R
e
f
e
r
e
n
c
e
S
u
b
j
e
c
t
s
D
e
s
i
g
n
G
l
n
C
o
n
t
r
o
l
O
u
t
c
o
m
e
s
R
e
s
u
l
t
s
B
a
r
b
o
s
a
e
t
a
l
.
1
9
9
9
[
1
1
0
]
9
c
r
i
t
i
c
a
l
l
y
i
l
l
i
n
f
a
n
t
s
a
g
e
d
1
–
2
4
m
o
r
e
q
u
i
r
i
n
g
i
n
t
e
n
s
i
v
e
c
a
r
e
a
n
d
t
o
l
e
r
a
t
i
n
g
E
N
R
a
n
d
o
m
i
z
e
d
d
o
u
b
l
e
-
b
l
i
n
d
G
l
n
s
u
p
p
l
e
m
e
n
t
e
d
0
.
3
g
/
k
g
/
d
E
N
f
o
r
5
d
(
n
=
5
)
C
a
s
e
i
n
s
u
p
p
l
e
m
e
n
t
e
d
0
.
3
g
/
k
g
/
d
E
N
f
o
r
5
d
(
n
=
4
)
S
e
p
t
i
c
m
o
r
b
i
d
i
t
y
,
m
o
r
t
a
l
i
t
y
,
L
O
S
i
n
I
C
U
,
L
O
S
i
n
h
o
s
p
i
t
a
l
a
n
d
d
u
r
a
t
i
o
n
o
f
m
e
c
h
a
n
i
c
a
l
v
e
n
t
i
l
a
t
i
o
n
,
a
n
d
t
o
l
e
r
a
n
c
e
N
o
s
i
g
n
i
ﬁ
c
a
n
t
d
i
ﬀ
e
r
e
n
c
e
s
i
n
s
e
p
t
i
c
c
o
m
p
l
i
c
a
t
i
o
n
s
,
m
o
r
t
a
l
i
t
y
,
d
i
n
I
C
U
,
d
i
n
h
o
s
p
i
t
a
l
o
r
d
w
i
t
h
v
e
n
t
i
l
a
t
i
o
n
,
w
e
l
l
t
o
l
e
r
a
t
e
d
,
a
n
d
s
a
f
e
M
e
r
c
i
e
r
e
t
a
l
.
2
0
0
3
[
1
1
2
]
2
5
L
B
W
p
r
e
m
a
t
u
r
e
n
e
o
n
a
t
e
s
a
g
e
≥
1
4
d
w
i
t
h
o
u
t
a
c
u
t
e
i
l
l
n
e
s
s
a
n
d
r
e
c
e
i
v
i
n
g
e
x
c
l
u
s
i
v
e
E
N
;
b
i
r
t
h
w
t
:
9
8
0
–
1
8
9
0
g
;
G
A
:
2
7
–
3
5
w
k
R
a
n
d
o
m
i
z
e
d
d
o
u
b
l
e
-
b
l
i
n
d
E
x
c
l
u
s
i
v
e
e
n
t
e
r
a
l
p
r
e
t
e
r
m
i
n
f
a
n
t
f
o
r
m
u
l
a
s
u
p
p
l
e
m
e
n
t
e
d
w
i
t
h
G
l
n
0
.
7
g
/
k
g
/
d
(
1
7
%
o
f
t
o
t
a
l
p
r
o
t
e
i
n
i
n
t
a
k
e
a
s
G
l
n
)
f
o
r
2
1
d
(
n
=
1
2
)
E
x
c
l
u
s
i
v
e
e
n
t
e
r
a
l
p
r
e
t
e
r
m
i
n
f
a
n
t
f
o
r
m
u
l
a
s
u
p
p
l
e
m
e
n
t
e
d
w
i
t
h
i
s
o
n
i
t
r
o
g
e
n
o
u
s
l
a
c
t
o
s
e
r
u
m
e
x
t
r
a
c
t
e
d
p
r
o
t
e
i
n
0
.
7
g
/
k
g
/
d
(
1
7
%
o
f
t
o
t
a
l
p
r
o
t
e
i
n
i
n
t
a
k
e
a
s
l
a
c
t
o
s
e
r
u
m
)
f
o
r
2
1
d
(
n
=
9
)
P
a
r
a
m
e
t
e
r
s
o
f
s
u
p
e
r
i
o
r
m
e
s
e
n
t
e
r
i
c
b
l
o
o
d
ﬂ
o
w
v
e
l
o
c
i
t
i
e
s
m
e
a
s
u
r
e
d
i
n
f
e
d
s
t
a
t
e
b
y
p
u
l
s
e
d
D
o
p
p
l
e
r
u
l
t
r
a
s
o
u
n
d
a
f
t
e
r
2
1
d
s
u
p
p
l
e
m
e
n
t
a
t
i
o
n
N
o
e
ﬀ
e
c
t
o
n
s
u
p
e
r
i
o
r
m
e
s
e
n
t
e
r
i
c
b
l
o
o
d
ﬂ
o
w
V
a
u
g
h
n
e
t
a
l
.
2
0
0
3
[
1
1
1
]
6
4
9
V
L
B
W
a
g
e
<
7
d
r
e
c
e
i
v
i
n
g
P
N
;
b
i
r
t
h
w
t
:
5
0
0
–
1
2
5
0
g
M
u
l
t
i
c
e
n
t
r
e
r
a
n
d
o
m
i
z
e
d
d
o
u
b
l
e
-
b
l
i
n
d
E
n
t
e
r
a
l
G
l
n
s
u
p
p
l
e
m
e
n
t
(
0
.
3
g
/
k
g
/
d
,
3
%
G
l
n
i
n
s
t
e
r
i
l
e
w
a
t
e
r
)
g
i
v
e
n
a
t
t
h
e
s
a
m
e
t
i
m
e
b
u
t
s
e
p
a
r
a
t
e
f
r
o
m
f
e
e
d
i
n
g
s
f
o
r
t
h
e
ﬁ
r
s
t
2
8
d
o
f
l
i
f
e
;
A
A
i
n
t
a
k
e
∼
3
–
3
.
5
g
/
k
g
/
d
b
y
d
7
(
n
=
3
1
4
)
E
n
t
e
r
a
l
p
l
a
c
e
b
o
(
s
t
e
r
i
l
e
w
a
t
e
r
)
g
i
v
e
n
a
t
t
h
e
s
a
m
e
t
i
m
e
b
u
t
s
e
p
a
r
a
t
e
f
r
o
m
f
e
e
d
i
n
g
s
f
o
r
t
h
e
ﬁ
r
s
t
2
8
d
o
f
l
i
f
e
;
A
A
i
n
t
a
k
e
∼
3
–
3
.
5
g
/
k
g
/
d
b
y
d
7
(
n
=
3
3
5
)
(
1
)
N
u
m
b
e
r
o
f
e
p
i
s
o
d
e
s
o
f
b
l
o
o
d
c
u
l
t
u
r
e
-
p
r
o
v
e
n
n
o
s
o
c
o
m
i
a
l
s
e
p
s
i
s
b
e
t
w
e
e
n
7
d
t
o
3
6
w
k
o
f
a
g
e
;
(
2
)
s
u
s
p
e
c
t
e
d
s
e
p
s
i
s
,
p
n
e
u
m
o
n
i
a
,
U
T
I
,
m
e
n
i
n
g
i
t
i
s
,
N
E
C
,
I
V
H
,
P
V
L
,
r
e
t
i
n
o
p
a
t
h
y
o
f
p
r
e
m
a
t
u
r
i
t
y
,
u
s
e
o
f
o
x
y
g
e
n
a
t
3
6
w
k
,
g
a
s
t
r
o
i
n
t
e
s
t
i
n
a
l
d
y
s
f
u
n
c
t
i
o
n
,
g
r
o
w
t
h
,
a
g
e
a
n
d
w
e
i
g
h
t
a
t
d
i
s
c
h
a
r
g
e
,
a
n
d
d
e
a
t
h
(
1
)
N
o
d
i
ﬀ
e
r
e
n
c
e
s
i
n
n
o
s
o
c
o
m
i
a
l
s
e
p
s
i
s
;
(
2
)
d
e
c
r
e
a
s
e
d
g
a
s
t
r
o
i
n
t
e
s
t
i
n
a
l
d
y
s
f
u
n
c
t
i
o
n
a
n
d
s
e
v
e
r
e
n
e
u
r
o
l
o
g
i
c
s
e
q
u
e
l
a
e
a
m
o
n
g
s
u
r
v
i
v
o
r
s
(
G
r
a
d
e
s
3
a
n
d
4
I
V
H
a
n
d
P
V
L
)
,
n
o
d
i
ﬀ
e
r
e
n
c
e
s
i
n
s
u
s
p
e
c
t
e
d
s
e
p
s
i
s
,
p
n
e
u
m
o
n
i
a
,
U
T
I
,
m
e
n
i
n
g
i
t
i
s
,
N
E
C
,
r
e
t
i
n
o
p
a
t
h
y
o
f
p
r
e
m
a
t
u
r
i
t
y
,
u
s
e
o
f
o
x
y
g
e
n
a
t
3
6
w
k
,
g
r
o
w
t
h
,
a
g
e
a
n
d
w
t
a
t
d
i
s
c
h
a
r
g
e
,
o
r
d
e
a
t
h
P
a
r
i
m
i
e
t
a
l
.
2
0
0
4
[
1
2
7
]
2
6
L
B
W
i
n
g
o
o
d
h
e
a
l
t
h
a
n
d
g
a
i
n
i
n
g
w
t
a
g
e
d
1
0
–
7
4
d
(
>
2
3
d
o
f
a
g
e
)
;
b
i
r
t
h
w
t
:
6
9
3
–
1
8
4
6
g
;
G
A
<
3
2
w
k
R
a
n
d
o
m
i
z
e
d
d
o
u
b
l
e
-
b
l
i
n
d
E
n
t
e
r
a
l
G
l
n
0
.
6
g
/
k
g
/
d
f
o
r
5
d
(
n
=
9
)
(
1
)
E
n
t
e
r
a
l
G
l
y
0
.
6
g
/
k
g
/
d
f
o
r
5
d
(
n
=
9
)
o
r
(
2
)
u
n
s
u
p
p
l
e
m
e
n
t
e
d
e
n
t
e
r
a
l
f
o
r
m
u
l
a
f
o
r
5
d
(
n
=
8
)
W
h
o
l
e
-
b
o
d
y
p
r
o
t
e
i
n
,
G
l
n
a
n
d
u
r
e
a
k
i
n
e
t
i
c
s
o
n
s
t
u
d
y
d
-
6
(
I
V
i
n
f
u
s
i
o
n
s
o
f
L
-
[
1
–
1
3
C
,
1
5
N
]
L
e
u
,
[
2
H
5
]
P
h
e
,
[
1
5
N
2
]
u
r
e
a
,
L
-
[
5
–
1
5
N
]
G
l
n
)
a
f
t
e
r
5
d
s
u
p
p
l
e
m
e
n
t
a
t
i
o
n
d
u
r
i
n
g
f
a
s
t
i
n
g
(
3
h
a
f
t
e
r
t
h
e
l
a
s
t
m
e
a
l
)
a
n
d
f
e
d
s
t
a
t
e
,
a
n
d
p
l
a
s
m
a
A
A
c
o
n
c
e
n
t
r
a
t
i
o
n
s
d
u
r
i
n
g
f
a
s
t
i
n
g
H
i
g
h
e
r
r
a
t
e
o
f
u
r
e
a
s
y
n
t
h
e
s
i
s
,
n
o
d
i
ﬀ
e
r
e
n
c
e
s
i
n
r
a
t
e
s
o
f
a
p
p
e
a
r
a
n
c
e
o
f
P
h
e
,
L
e
u
C
o
r
L
e
u
N
,
n
o
d
i
ﬀ
e
r
e
n
c
e
s
i
n
r
a
t
e
o
f
a
p
p
e
a
r
a
n
c
e
o
f
G
l
n
o
r
p
l
a
s
m
a
G
l
n
c
o
n
c
e
n
t
r
a
t
i
o
n
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T
a
b
l
e
2
:
C
o
n
t
i
n
u
e
d
.
R
e
f
e
r
e
n
c
e
S
u
b
j
e
c
t
s
D
e
s
i
g
n
G
l
n
C
o
n
t
r
o
l
O
u
t
c
o
m
e
s
R
e
s
u
l
t
s
K
o
r
k
m
a
z
e
t
a
l
.
2
0
0
7
[
1
2
3
]
6
9
V
L
B
W
p
r
e
m
a
t
u
r
e
n
e
o
n
a
t
e
s
r
e
c
e
i
v
i
n
g
P
N
;
b
i
r
t
h
w
t
:
<
1
5
0
0
g
P
r
o
s
p
e
c
t
i
v
e
i
n
t
e
r
v
e
n
t
i
o
n
F
r
o
m
8
d
t
o
1
2
0
d
o
f
l
i
f
e
r
e
c
e
i
v
e
d
G
l
n
s
u
p
p
l
e
m
e
n
t
0
.
1
5
g
/
k
g
/
d
B
I
D
m
i
x
e
d
w
i
t
h
s
t
e
r
i
l
e
w
a
t
e
r
a
n
d
g
i
v
e
n
a
t
t
h
e
s
a
m
e
t
i
m
e
b
u
t
s
e
p
a
r
a
t
e
f
r
o
m
f
e
e
d
i
n
g
s
b
y
a
n
o
r
o
g
a
s
t
r
i
c
t
u
b
e
o
r
o
r
a
l
l
y
(
n
=
3
6
)
F
r
o
m
8
d
t
o
1
2
0
d
o
f
l
i
f
e
r
e
c
e
i
v
e
d
s
t
e
r
i
l
e
w
a
t
e
r
(
p
l
a
c
e
b
o
)
g
i
v
e
n
a
t
t
h
e
s
a
m
e
t
i
m
e
b
u
t
s
e
p
a
r
a
t
e
f
r
o
m
f
e
e
d
i
n
g
s
b
y
a
n
o
r
o
g
a
s
t
r
i
c
t
u
b
e
o
r
o
r
a
l
l
y
(
n
=
3
3
)
G
r
o
w
t
h
p
a
r
a
m
e
t
e
r
s
a
t
b
i
r
t
h
,
1
,
2
,
3
,
a
n
d
4
m
o
a
n
d
b
i
o
c
h
e
m
i
c
a
l
p
a
r
a
m
e
t
e
r
s
a
t
4
m
o
N
o
d
i
ﬀ
e
r
e
n
c
e
s
i
n
g
r
o
w
t
h
p
a
r
a
m
e
t
e
r
s
a
t
b
i
r
t
h
a
n
d
2
m
o
,
h
i
g
h
e
r
w
t
,
l
e
n
g
t
h
,
h
e
a
d
c
i
r
c
u
m
f
e
r
e
n
c
e
,
M
U
A
C
a
n
d
m
i
d
-
t
h
i
g
h
c
i
r
c
u
m
f
e
r
e
n
c
e
a
t
3
a
n
d
4
m
o
,
n
o
t
o
x
i
c
i
t
y
s
i
g
n
s
V
a
n
D
e
n
B
e
r
g
e
t
a
l
.
2
0
0
5
∗
∗
[
1
1
3
]
1
0
2
V
L
B
W
<
4
8
h
a
f
t
e
r
b
i
r
t
h
r
e
c
e
i
v
i
n
g
P
N
;
b
i
r
t
h
w
t
:
<
1
5
0
0
g
;
G
A
<
3
2
w
k
R
a
n
d
o
m
i
z
e
d
d
o
u
b
l
e
-
b
l
i
n
d
F
r
o
m
3
d
t
o
3
0
d
o
f
l
i
f
e
r
e
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enteral formula supplemented with 0.3g/kg/d Gln for 5 days
versusanequaldoseofcaseinin9criticallyillinfantsaged1–
24 months. Although Gln was well tolerated, the study was
underpowered to detect diﬀerences in septic complications
(control: 3/4 versus Gln: 1/5, P = 0.10), mortality (control:
2/4 versus Gln: 0/5, P = 0.10) or other outcomes (ventilator
use,lengthofstayinintensivecareunit(ICU)orinhospital).
It was also not reported in the inclusion criteria whether the
study population of infants were premature or term.
Vaughn et al. [111]c o n d u c t e dal a r g em u l t i c e n t r et r i a lt o
test whether enteral Gln supplement decreases the incidence
of hospital-acquired infection and other morbidities in 649
VLBW infants. Within the ﬁrst 7d of age, infants were
randomly assigned to enteral Gln supplement (0.3g/kg/d,
3% Gln in sterile water) or placebo (sterile water) given at
the same time but separate from feedings for the ﬁrst 28d.
There were no diﬀerences between groups for the primary
outcome (nosocomial sepsis between 7d and 36 weeks post-
menstrual age; Gln: 30.9% versus control: 33.7%). However,
gastrointestinal dysfunction (2.5 versus 7.5%, P<0.01)
and severe neurological sequelae among survivors (Grades
3 and 4 intraventricular hemorrhage and paraventricular
leukomalacia; 10.4 versus 15.1%, P = 0.08) were less
frequent in Gln versus control, respectively. There were no
diﬀerencesintheoccurrenceofsuspectedsepsis,pneumonia,
urinary tract infection, meningitis, NEC, retinopathy of
prematurity, oxygen use at 36 weeks, or mortality. Growth,
age, and weight at discharge were also similar. Whereas
enteral Gln does not appear to decrease nosocomial sepsis
in VLBW infants, the study may have been underpowered
to detect a signiﬁcant diﬀerence, as dropout rate was higher
than anticipated (i.e., 105 infants exited the study before
completion). Also the centre-to-centre variation in this and
othermulticentretrials[102]mayhaveblunteddiﬀerencesin
outcomes (e.g., sepsis), since nutrition and infection control
practices may diﬀer among centres and may mask some of
the diﬀerences that might be apparent in a single facility.
While the study provides further evidence to suggest that
enteral Gln improves feeding tolerance and may prevent
central nervous system (CNS) morbidity, these positive
results are based on secondary endpoints and subgroup
analyses. Furthermore, the Gln dose was based on birth
weight and was not adjusted for interval changes in weight.
Therefore, the dose administered may have been inadequate
due to rapid growth during the early neonatal period.
The apparent improved feeding tolerance in VLBW
infants receiving enteral Gln in previous studies [107, 111]
cannot be explained by enhanced mesenteric blood ﬂow
[112]. It seems that, in premature infants without acute
illness and tolerating exclusive EN, mesenteric blood ﬂow
remains stable after 14d of age and does not appear to be
inﬂuenced by enteral Gln.
In contrast to previous reports on Gln-enriched EN in
VLBWinfants[107,111],VanDenBergetal.[113]foundno
improvement in feeding tolerance, as assessed by the median
d to reach full enteral feeds (Gln: 13d versus control: 13d;
hazard ratio [95% CI]: 1.19 [0.79–1.79]). In this randomized
controlledtrial,102VLBWinfantsreceivedeitherenteralGln
supplementationoranisonitrogenouscontrol(Ala)addedto
breast milk or preterm formula in increasing doses from d-3
to d-30 of life to a maximum dose of 0.3g/kg/d Gln. There
were also no diﬀerences between groups for other variables
of feeding tolerance (age at which PN was discontinued, d
of no enteral feeding), NEC, or growth. However, the Gln-
supplemented group had a lower incidence of ≥1s e r i o u s
infections (sepsis, meningitis, pyelonephritis, pneumonia,
and arthritis) compared with the isonitrogenous control
group (Gln: 50% versus control: 76%; OR [95% CI]: 0.32
[0.14–0.74]. Other short-term outcomes (patent ductus
arteriosus treated with indomethacin or surgical ligation,
mechanical ventilation, supplemental oxygen, retinopathy,
age at discharge from NICU, age at discharge from hospital,
or death) were not signiﬁcantly diﬀerent. Gln did not alter
plasma concentrations of Gln, Glu, or other amino acids
[114]. Although safe at the dose provided, Gln-enriched
EN did not improve feeding tolerance or other short-
term outcomes in VLBW infants. However, because Gln
reduced infectious morbidity, the use of Gln-enriched EN in
VLBW infants deserves further consideration. Comparison,
however, with other studies is made diﬃcult because of the
use of diﬀerent feeding guidelines for the introduction or
withholding enteral feeds. Whereas the choice of isonitroge-
nous control prevented the removal of amino acids from
the Gln supplement in the present study, groups were made
isonitrogenous by adding more amino acid (Ala) to the
control group. The control group then received additional
amino acid/nitrogen, which is not representative of daily
practice. However, given the limited sample size, a third
comparison group (enteral formula routinely used in an
NICU) was not feasible. The beneﬁcial eﬀect of enteral Gln
on infection rate could not be explained by an increased
number of biﬁdobacteria or lactobacilli in the intestinal
microﬂora as demonstrated by a secondary analysis in a
subset of 86 VLBW infants [115]. Furthermore, Gln did not
enhance the postnatal decrease in intestinal permeability,
as assessed by the urinary lactulose/mannitol ratio in a
subset of 90 VLBW infants. Speciﬁcally, supplementation
withGlnorisonitrogenouscontrolequallydecreasedurinary
concentrations of lactulose and increased urinary mannitol
[116]. More recently, followup of all surviving participants
(n = 77) revealed that Gln-enriched EN in VLBW infants
may lower the incidence of atopic dermatitis (OR [95%
CI]: 0.13 [0.02–0.97]) during the ﬁrst year of life but has
no eﬀect on the incidence of bronchial hyperactivity or
infectious diseases [117]. Further followup of this cohort
of VLBW infants (n = 76) at 6y of age also found a
decreased risk of atopic dermatitis (adjusted OR [95% CI]:
0.23 [0.06–0.95]) and gastrointestinal infections (adjusted
OR [95% CI]: 0.10 [0.01–0.93]) in the Gln-supplemented
group [118]. Although outcomes were assessed by validated
questionnaires in these 2 followup studies, parental report
of physician diagnosis of disease could be subject to report-
ing/information bias. Furthermore, the lower incidence of
atopic dermatitis and infection rates with Gln were not
related to changes in cytokine proﬁles [119]/responses [120]
or to changes in intestinal bacterial species at age 1y
[121]. Finally, the same group studied neurodevelopmental
outcome at 2y corrected age in a subgroup of 72 VLBWJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 15
infants and found no beneﬁcial eﬀect of Gln-enriched EN
during the neonatal period [122].
The eﬀect of Gln supplementation on long-term out-
come of VLBW infants has also been reported by Korkmaz
et al. [123] who studied the eﬀect of 4-month enteral Gln
supplementation on growth. From d-8 through d-120 of life,
69 VLBW infants were assigned to enteral Gln (0.3g/kg/d)
supplement or placebo (sterile water) according to the order
of admission to the NICU. Whereas growth parameters did
not diﬀer during the ﬁrst 2 months of life, by the end of
the third and fourth month, infants treated with Gln showed
higher weight, length, head circumference, mid-upper-arm
circumference, and midthigh circumference compared to
controls. The authors concluded that long-term enteral Gln
in VLBW infants may lead to improvements in growth in a
time-dependent manner without any signs of Gln toxicity.
Although this was a prospective interventional study, a com-
plete description of masking, blinding, or randomization
procedures was not provided. Also, because the placebo
(sterile water) was neither isocaloric nor isonitrogenous to
the Gln treatment, the enhanced growth could have resulted
from the eﬀect of increased amino acid/nitrogen, since early
provision of parenteral amino acids (without Gln) has been
shown to improve growth parameters in VLBW infants
[124].
3.2.2. Protein Metabolism. Darmaun et al. [125] determined
the eﬀect of enteral Gln on Leu and Gln metabolism in
a subset of 11 VLBW neonates from the larger trial [107]
(Table 2). Enteral Gln supplementation provided at low
doses (≤0.2g/kg/d) from d-3 to d-10 of life did not inhibit
whole-bodyproteinbreakdowninVLBWinfants.Leurelease
from protein breakdown (an index of whole-body protein
breakdown) was slightly but not signiﬁcantly lower in the
Gln group versus controls. Plasma Gln concentration, Gln
releasefromprotein breakdown, or Gln de novo synthesisdid
not signiﬁcantly diﬀer between groups. However, there was a
trend toward lower rates of Gln de novo synthesis in infants
receiving Gln supplement. Although the number of patients
wassmall,thefailuretodetectasigniﬁcanteﬀectofGlnonits
ownmetabolismoronwhole-bodyproteinbreakdowncould
also be due to the diﬀerent eﬀects of enteral and parenteral
Gln supplementation. Importantly, the majority of enteral
G l ni su s e di nﬁ r s tp a s si np r e m a t u r ei n f a n t s[ 126]. This is
likely a signiﬁcant factor in the diﬀerent eﬀects of enteral and
parenteralGln.Moreover,thedoseofGlnusedinthecurrent
study was lower than that (0.5g/kg/d Gln) previously shown
to inhibit proteolysis in LBW infants [105].
Parimi et al. [127] examined the eﬀect of enteral
Gln on whole-body Gln and nitrogen kinetics in healthy
growing LBW infants during the fasting (3h after the last
meal) and fed state. This study was the only to have 3
groups, where Gln-supplemented group was compared with
an isonitrogenous control and enteral formula routinely
used in the NICU. Between 10 and 74d of age, infants
were randomly assigned to formula supplemented with Gln
(0.6g/kg/d; n = 9), isonitrogenous amounts of Gly (n =
9), or unsupplemented formula (n = 8) for 5d. During
fasting, the rate of appearance of Phe, Leu carbon, and
Leu nitrogen (measures of proteolysis) were not signiﬁcantly
diﬀerent between groups. Compared with controls, enteral
Gln resulted in an increased rate of urea synthesis, no change
in Gln rate of appearance, or plasma Gln concentrations.
Similar eﬀects were observed with Gly supplement, but the
magnitude was less. The authors concluded that enteral Gln
does not aﬀectGln rate of appearance or whole-body protein
turnover in a speciﬁc group of healthy growing LBW infants,
thus, suggesting that Gln is primarily metabolized in the gut
(and liver) [126] and is associated with an increased rate of
urea synthesis. Alternatively, because, in healthy premature
newborns, there is already a high rate of Gln turnover (85%
of which is contributed by de novo synthesis) [128], this
speciﬁc population of neonates could have been less sensitive
to enteral Gln. This is in contrast to premature neonates with
acute illness, whereby catabolic stress may provoke a greater
need for exogenous Gln.
In summary, although methodologically sound random-
ized trials consistently demonstrate safety in VLBW infants
[80, 99, 100, 102, 105, 107, 111, 113, 127], parenteral
or enteral Gln supplementation does not appear to aﬀect
mortality [100, 102, 104, 107, 111, 113], NEC [100, 102, 107,
111, 113], length of stay [99, 100, 102, 104, 107, 111, 113],
or growth [100, 102, 104, 107, 111, 113]. Moreover, the
results are conﬂicting for other short-term clinical outcomes
such as feeding tolerance [99, 100, 102, 104, 107, 111, 113],
serious infections/sepsis [100, 102, 107, 111, 113], ventilator
use [99, 102, 104, 107, 113], and severe neurological sequelae
[111] .F e wd a t ah a v eb e e nr e p o r t e df o rt h ee ﬀects of Gln
supplementation in VLBW infants on long-term clinical
outcomes such as growth at 4 months [123], allergic and
infectious morbidity at 1y [117]a n d6 y[ 118], and neu-
rodevelopmental outcomes at 2y corrected age [122]. Larger
well-controlled studies are needed. A systematic review of
7 randomized controlled trials showed that parenteral or
enteral Gln supplementation in premature infants of VLBW
does not aﬀect mortality (RR [95% CI]: 0.98 [0.80–1.20])
orotherclinicaloutcomesincluding invasive infection,NEC,
time to achieve full EN, duration of hospital stay, growth, or
neurodevelopmental outcomes at 18 months corrected age
[129].
In contrast, studies on protein metabolism showed that
parenteral Gln may have a protein-sparing eﬀect decreasing
whole body proteolysis and Gln de novo synthesis in
premature infants of LBW [80, 105]. However, the beneﬁcial
eﬀects on whole-body protein metabolism have not been
reproduced for enteral Gln [125, 127]. Hence, the route
of administration (enteral versus parenteral) should be
considered in interpreting the eﬀect of Gln on outcome in
premature infants [126].
ParenteralandenteralGlnsupplementationisapparently
safe in premature neonates; however, the lack of any
consistent beneﬁt(s) does not support its routine use in this
population as a whole. It is possible that any beneﬁcial eﬀects
of Gln are limited to speciﬁc subgroups of premature infants
suﬀering from acute stress (e.g., NEC, who are perhaps Gln
or Arg deﬁcient [88]) whereby increased Gln utilization
exceeds the body’s synthetic capacity [10]. Future studies16 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
are needed to better deﬁne the role of Gln in the neonatal
period and its mechanism of action. Large prospectively
stratiﬁed trials are needed to identify the speciﬁc subgroups
of premature neonates, who may have a greater need for Gln
and who may eventually beneﬁt from Gln supplementation.
3.3. Glutamine Supplementation in Pediatric Patients with
Gastrointestinal Disease
3.3.1. Glutamine Supplementation in Infants with Surgical
Gastrointestinal Disease. While several trials have been con-
ducted in VLBW infants, only 2 small double-blinded
randomized trials tested whether supplemental Gln might be
of beneﬁt in critically ill infants with surgical gastrointestinal
disease [130, 131]( Table 3). Duggan et al. [130]c o m p a r e d
enteral Gln to an isonitrogenous mix of nonessential amino
acids in 20 neonates and infants younger than 12 months
receiving PN after gastrointestinal surgery and found no
apparent eﬀect on the duration of PN (Gln: 39d versus
control:21d,NS)ordaystoachieve80%energyrequirement
by EN (Gln: 24d versus control: 13d, NS). Secondary
outcomes (energy absorption, clinical infections, or growth)
were also not aﬀected by enteral Gln. Albers et al. [131]
compared standard PN to isonitrogenous Gln-supplemented
PN in 80 newborns and infants (<2y of age) after major
digestive-tract surgery and concluded that parenteral Gln
supplementation does not improve intestinal permeability
(urinary excretion of lactulose/rhamnose), nitrogen balance,
urinary 3-methyl-histidine excretion, or other outcomes
(mortality, length of stay in the ICU or hospital, culture-
proven sepsis, usage of antibiotics, or ICU resources).
Although no adverse eﬀects were identiﬁed, both trials as
well as meta-analysis for 2 outcomes (in hospital mortality
and incidence of invasive infection) [132]d on o ts u p p o r t
the use of parenteral or enteral Gln supplementation in
surgical infants with severe gastrointestinal disease until
further research proves otherwise.
There are a number of possible explanations for the
indeterminate results. Firstly, along with the small sample
size, the heterogeneous nature of the infants enrolled may
have contributed to the substantial variability in the primary
outcome and secondary outcomes and thus limited the
power of detecting diﬀerences. Whereas the target dose of
0.4g/kg/d may have allowed Gln supplementation to have
an eﬀect, the actual cumulative intake of Gln may not have
been adequate to exert its eﬀects. For instance, in the study
by Albers et al. [131], tapering of PN (and hence Gln) was
allowed to begin only 2d after 90% of the Gln dose had been
achieved, whereas, in that by Duggan et al. [130], inadequate
Gln intake may have been due to the gradual advancement of
ENandintermittentinterruptionoffeedsrequiredbyinfants
who had undergone intestinal resection. Alternatively, the
dose may have been inadequate when administered by the
enteral route in this population, since infants may not
have absorbed the entire dose of enteral Gln due to their
gastrointestinal disease and possible malabsorption [130].
Furthermore, patients fed enterally may require greater
protein or amino acids to meet requirements versus those
fed parenterally [133]. In addition to the potential eﬀect
of route and dose of Gln administration, total nitrogen
intakemayhavebeeninadequate[131],sincenitrogenintake
plateaued at 90% of target (<1.5g/kg/d amino acids), which
is lower than the recommended daily allowance for LBW
infants or the minimum amount of amino acid needed to
preventproteinbreakdown[134].Finally,theisonitrogenous
design whereby predetermined amounts of essential and
otheraminoacidsweresubstitutedwithGln(asinthestudies
with VLBW infants) may have obscured potential beneﬁts
of Gln supplementation. Large prospectively stratiﬁed trials
are needed to control for these and other variables that
might aﬀect outcome and deﬁne precise indications or
contraindications for Gln supplementation.
3.3.2. Glutamine Supplementation in Short Bowel Syndrome.
Intestinal failure is the inability to maintain nutritional and
ﬂuid balance without nutritional support [135]. Short bowel
syndrome (SBS) is the result of malabsorption secondary to
extensive intestinal resection. The aim in the management of
SBS is to enhance intestinal adaptation of the remaining gut
in an attempt to achieve intestinal autonomy [135].
Although Gln reduces PN dependence when taken in
combinationwithgrowth hormoneinadultswithSBS[136],
there is a lack of data on the role of Gln in pediatric
patientswiththiscondition.ComparedtoadultSBSpatients,
pediatric patients require additional energy and nutrients for
growth. Similarly, we have observed increased turnover of
protein and Gln in infants compared to adults, regardless
of intestinal status [137]. Importantly, previous data from
our group also suggests that the infant small intestine plays
a prominent role in Gln metabolism and may also be a
preferential userof Gln. Speciﬁcally,we observed a lower rate
of whole-body Gln production and utilization in SBS infants
compared to control infants, whereas whole-body protein
turnover (Leu appearance rate) was unaltered by intestinal
resection [137].
Apart from isolated case reports documenting improve-
ments in weight [138, 139], body composition [139], intesti-
nal permeability [138], stool output [138], and nitrogen
retention [139] after supplemental Gln, data are lacking
in pediatric patients with SBS (Table 3). In a retrospective
review of the medical records of 2 pediatric patients with
SBS from neonatal gastrointestinal catastrophes, Ladd et al.
[140] observed that late treatment (at ∼6y of age) with
growth hormone and concurrent enteral Gln (30mg/d)
supplementation given over long periods improved growth
and resulted in PN independence.
Data derived from adults and children with SBS are
l i m i t e dt oc a s es e r i e s[ 141, 142] reporting that supplemental
Gln (0.6g/kg/d) over long periods in combination with
growth hormone and rehabilitative diet resulted in improved
weight [142], plasma proteins [141, 142], intestinal absorp-
tive capacity [141, 142], and weaning from PN [141].
In the above reports, because patients were also receiving
other medical therapy, it is not clear whether Gln, growth
hormone, diet, or other factors contributed to the favourable
outcome. Although no side eﬀects have been reported,
data to date are solely hypothesis generating and cannot
conﬁrm any beneﬁt of supplemental Gln in promotingJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 17
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intestinal adaptation in pediatric SBS patients. Due to the
small number of pediatric patients, lack of control group,
and wide patient age range, larger randomized placebo
controlled trials of good methodological quality are war-
ranted, especially in children with SBS to delineate whether
Gln alone or in combination with other therapies (e.g.,
growth hormone) is eﬃcacious in intestinal adaptation. This
highlights the need for further studies to deﬁne speciﬁc
selection criteria with respect to patient age (e.g., infants or
children). Consideration should also be given to the timing
of treatment initiation, that is, the duration between intesti-
nal resection and start of treatment (e.g., early versus late
treatment).
3.3.3. Enteral Glutamine in Children with Crohn’s Disease.
Children with active Crohn’s disease undergo catabolic
stress, demonstrating increased rates of whole-body protein
turnover [143]. Whereas animal models of IBD have indi-
catedpotentially beneﬁcialeﬀectsof supplementalGln [144–
146], clinical studies of Gln in inﬂammatory bowel disease
(IBD) have been less encouraging [147–149].
Akobeng et al. published a series of reports [148, 150–
152]( Table 3) from a group of 18 children (aged 6.8–15.7y)
with active Crohn’s disease who participated in a double-
blind randomized controlled trial comparing the eﬃcacy of
4 weeks exclusive enteral Gln-enriched polymeric diet (42%
of amino acids as Gln) with a standard polymeric diet (4% of
amino acids as Gln) that was isocaloric and isonitrogenous
[148]. The initial trial found no evidence that Gln-enriched
polymeric EN is of any beneﬁt over standard polymeric EN
in the treatment of children with active Crohn’s disease.
After 4 weeks of exclusive EN, there were no diﬀerences in
remission rates (4/9 in Gln versus 5/9 in control), changes in
platelet count, orosomucoid level, or weight. Gln, however,
was less eﬀective in improving indices of disease activity
(pediatricCrohn’sdiseaseactivityindex(PCDAI))compared
to standard diet.
Secondaryanalysesinasubsetofchildrenfromtheinitial
trial also showed that Gln was equivalent to isonitrogenous
standard in attenuating increased intestinal permeability
[150] or improving plasma antioxidant status [152], possible
factors in the pathogenesis of Crohn’s disease. Furthermore,
Gln-enriched EN did not lead to any improvement in the
reduced IGF1 concentrations described in children with
Crohn’s disease and was actually less eﬀective than standard
isonitrogenous EN in improving impaired growth in these
children [151].
The inconclusive results could be explained by baseline
diﬀerencesinthePCDAI,which(althoughadjustedforinthe
analysis) may have contributed to the greater improvement
in PCDAI with the standard diet. It is also possible that
such a high concentration of Gln used in the present study
may have exceeded the optimal concentration of Gln, that
is, beneﬁcial and may actually be harmful in IBD [153].
Gln might have caused excessive priming of immune cells
[154], which in turn may promote inﬂammatory activity.
This highlights the need for dose-ﬁnding studies in this
population.Alternatively,substitutionof42%ofaminoacids
with Gln may have led to an imbalance in the amino acid
proﬁle.
Results are indeterminate from this one small trial [148].
Moreover, 2 children (both from the Gln group) were
withdrawnfromthetrial,becauseofnontoleranceofthediet.
Mechanistic data are needed to better understand how Gln
interactswithdiseasepathogenesisandtodeterminewhether
Gln is in fact contraindicated or beneﬁcial in children with
Crohn’s disease, and if so at which doses. Fundamental
research is needed before any further randomized controlled
trials can be conducted with larger numbers of these
children.
3.4. Enteral Glutamine in Children with
Diarrheal Disease/Malnutrition
3.4.1.EnteralGlutamineSupplementationinInfantsandChil-
dren with Diarrhea. In animal models (rat and rabbit) of
secretory diarrhea induced by cholera toxin, Gln-based oral
rehydration solution (ORS) was more eﬀective in inducing
the absorption of electrolytes and water versus glucose-
based ORS [155, 156]. Similarly, in experimental bacterial
diarrhea using the Escherichia coli model, Gln-containing
ORS corrected plasma volume and prevented signiﬁcant
weight loss in diarrheic calves [157]. Likewise, infected
rabbits also show enhanced intestinal sodium absorption
with enteral Gln treatment [158]. In children, amino acids
(e.g., Gln) may have facilitating eﬀects on fructose and
sorbitol absorption [159].
Three double-blind randomized controlled trials have
tested the eﬃcacy of oral Gln in the treatment of diarrheal
disease in infants and children [160–162]( Table 4). Ribeiro
Jr. et al. [160] studied 118 infants (1–12 months of age) with
acute noncholera diarrhea and dehydration and reported
that Gln-based ORS did not provide additional beneﬁt over
the standard World Health Organization (WHO)-ORS with
respect to diarrheal stool output, duration of diarrhea, or
volume of ORS needed to achieve/maintain hydration. This
initial trial was generally of good methodological quality;
however, the addition of Gln to the standard WHO-ORS
led to a higher osmolality versus standard, and osmolality
could aﬀect diarrheal symptoms. More recently, Gutierrez
et al. [162] have compensated for the hyperosmolality by
testing an ORS in which glucose was replaced with Gln
in 147 dehydrated children (aged 1–60mo) with acute
diarrhea compared to standard glucose-based WHO-ORS.
Although solutions were of similar osmolality, glucose-free
Gln-based ORS did not appear to reduce stool output,
volume of ORS or time required for rehydration, urine
output, or vomiting. The indeterminate results of both
trials could be explained by subjects being only mildly to
moderately dehydrated, since ORS is more eﬀective when
given to dehydrated patients [160, 161]. Furthermore, the
early feeding just after rehydration may have blunted the
eﬀects of Gln [160]. Finally, Gln may have a lesser eﬀect
on intestinal absorption of water and sodium in noncholera
diarrhea compared to when the secretory component of
the diarrheal episode is more severe (i.e., when there is a
relativelylargersecretionofsodiumandchloride)[155,156].20 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 4: Enteral glutamine supplementation in children with diarrheal disease/malnutrition.
Reference Subjects Design Gln Control Outcomes Results
Ribeiro Jr.
et al. 1994
[160]
118 male infants
aged 1–12mo
with acute
noncholera
diarrhea and
dehydration
Randomized
double-blind
Oral Gln
(90mmol/L)
added to standard
glucose-based
(90mmol/L)
WHO-ORS
(n = 59)
Standard
glucose-based
(111mmol/L)
WHO-ORS
(n = 59)
(1) Duration and
severity (stool
output, stool
output rate) of
diarrhea and (2)
intake of ORS
(recorded at 6h
intervals in a
metabolic unit),
urine output,
vomitus, body wt,
blood gases, and
electrolytes
monitored during
hospitalization
(1) No diﬀerences in
diarrheal stool output,
stool output rate, or
duration of diarrhea,
(2) no diﬀerences in
volume of ORS to
achieve and maintain
hydration, amount and
number of vomitus,
urine output, wt gain,
safe, and well tolerated
Yalc ¸inetal.
2004 [161]
128 otherwise
healthy children
aged 6–24mo
with acute
(<10d) diarrhea
Randomized
double-blind
Oral Gln
(0.1g/kg/d TID)
capsules dissolved
in water for 7d
(n = 63)
Oral placebo
(cornstarch)
capsules dissolved
in water for 7d
(n = 65)
(1) Duration of
diarrhea, (2)
severity of
diarrhea by
mother
self-report
followed until
end of diarrheal
episode,
immunologic
parameters 7d
after treatment,
wt gain and
infectious disease
monitored
monthly until 3
months after
treatment
(1) Shorter duration of
diarrhea for entire
cohort and for age
≥12mo subgroup, (2)
no diﬀerences in
frequency of persistent
diarrhea or vomiting,
no diﬀerences in serum
IL-8, salivary
immunoglobulin A, wt
gain or frequency of
infections
Gutierrez et
al. 2007
[162]
147 dehydrated
children aged
1–60mo with
acute noncholera
diarrhea
Randomized
double-blind
WHO-ORS in
which glucose
was replaced with
Gln (20g/L) until
rehydration
(n = 73)
Standard
glucose-based
WHO-ORS until
rehydration
(n = 74)
Eﬃcacy in
reducing (1) stool
volume and (2)
rehydratation
time in acute
diarrhea
(1) No diﬀerences in
stool output during
ﬁrst 4h, (2) no
diﬀerences in time to
successful rehydration,
volume of ORS
required for
rehydration, urine
output, or vomiting
Lima et al.
2005 [168]
80 malnourished
(WAZ < −2)
hospitalized
children aged
2–60mo with or
without diarrhea
Randomized
double-blind
Gln-
supplemented
(16.2g/d) enteral
modiﬁed WHO
formula for 10d
(n = 26)
(1) Modiﬁed
WHO enteral
formula standard
(n = 27 not
randomized) or
( 2 )i s o m o l a rG l y -
supplemented
(8.3g/d) enteral
modiﬁed WHO
formula for 10d
(n = 27)
(1) Intestinal
permeability
(urinary lactu-
lose/mannitol
ratio), (2) wt gain
after 10d
supplementation
(1) Improvement in
intestinal barrier
function (decreased
lactulose/mannitol
ratio versus Gly or
standard), (2) no eﬀect
on % urinary excretion
of lactulose or
mannitol or on
duration of diarrhea,
no diﬀerences in wt
gain, no improvement
in WAZ, safe, and well
toleratedJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 21
Table 4: Continued.
Reference Subjects Design Gln Control Outcomes Results
Lima et al.
2007 [169]
107
malnourished
(WAZ, HAZ, or
WHZ < −1)
children aged
7.9–82.2mo in
northeastern
Brazil
Randomized
double-blind
phase III
Oral alanyl-Gln
(24g/d) mixed
with whole milk
for 10d (n = 51)
Oral
isonitrogenous
Gly (25g/d)
mixed with whole
milk for 10d
(n = 56)
(1) Intestinal
permeability
(urinary lactu-
lose/mannitol
ratio) 10d after
supplementation,
(2) growth (wt
and height)
measured until
d120 of study,
diarrheal disease
morbidity
(1) No eﬀect on
lactulose/mannitol
ratio, (2) improvement
in barrier function
(decrease in %
lactulose recovery),
reduction in absorptive
epithelium (decrease in
% mannitol recovery),
improved (increased)
cummulative change
over 120d in WHZ and
WAZ but not HAZ
(after adjustment for
age and season), safe
a n dw e l lt o l e r a t e d
Williams et
al. 2007
[167]
93 malnourished
growth-faltering
Gambian infants
aged 4–11mo
Randomized
double-blind
Oral Gln
0.25g/kg/d BID
mixed with
expressed
breastmilk or
distilled water for
5-6mo (rainy
season) (n = 46)
Oral
isonitrogenous
isocaloric mix of
nonessential AA
(Ala, Gly, Ser,
Asn; 0.25g/kg/d
BID) and fructose
mixed with
expressed
breastmilk or
distilled water for
5-6mo (rainy
season) (n = 47)
(1) Growth and
intestinal barrier
function
(intestinal
permeability)
measured
monthly during
5mo
supplementation
and 6mo after,
(2) plasma
markers of
immunostimula-
tion
(immunoglobu-
lins and acute
phase proteins)
during
supplementation
and morbidity (as
reported by
mother)
(1) No improvement in
wt gain or length gain,
no improvement in
lactulose/mannitol
intestinal permeability
ratio or % urinary
lactulose or mannitol
recovery, (2) no eﬀect
on plasma
concentrations of
immunoglobulins or
acute phase proteins or
on morbidity
WHO: World Health Organization; ORS: oral rehydration solution; wt: weight; TID: 3 times a day; IL: interleukin; WAZ: weight for age z-score; HAZ: height
for age z-score; WHZ: weight for height z-score; BID: twice a day; AA: amino acid.
For instance, in pig rotavirus enteritis, Gln stimulates jejunal
sodium and chloride absorption [163].
Yalc ¸in et al. [161] administered oral Gln (0.3g/kg/d) as
capsules for 7d in 128 otherwise healthy infants aged 6 to
24 months with acute diarrhea. Compared to cornstarch
placebo, Gln reduced the duration of diarrhea (Gln: 3.40 ±
1.96d versus placebo: 4.57 ± 2.48d, P<0.01) for the
entire cohort and among infants aged ≥12mo, but not
for infants <12mo. The frequency of persistent diarrhea
(Gln: 2/63 versus placebo: 6/65) or vomiting (Gln: 24/63
versus placebo: 32/65) was not signiﬁcantly diﬀerent. Serum
interleukin-8 was signiﬁcantly less after 7-d treatment in
bothgroupswithnodiﬀerencebetweengroups,whereassali-
vary immunoglobulin A showed no change. No diﬀerences
in leukocyte counts, lymphocyte counts, or lymphocyte
subpopulations were observed between Gln-supplemented
and placebo groups [164]. Furthermore, during the 3
months after treatment, mean weight gain and incidence of
infections were similar in both groups. Thus, the reduction
in diarrheal duration by Gln seems to result from its local
beneﬁcial eﬀect on the gastrointestinal mucosa rather than
a modulation of the immune response. Alternatively, the
lack of immunomodulatory eﬀect may have been partly
attributed to patient selection of children with mild to
moderate diarrhea, who may have responded diﬀerently to
those with persistent or secretory diarrhea. It is also possible
that some infants received Gln from breast milk and, thus,
were not in fact truly Gln deﬁcient, especially infants <12mo
(which could explain the lack of eﬀect in this subgroup).
The results, however, should be taken with caution as the
primary outcome was a subjective measure based on patient
self-report (i.e., clinical recovery as described by the mother22 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
and noted in an observation chart given to the mother).
Also the small number of children may have limited the
statistical power to detect changes in complications that are
less frequent (e.g., frequency of persistent diarrhea).
3.4.2. Enteral Glutamine Supplementation in Malnourished
Infants and Children. In the malnourished growing rat,
Gln-enriched diet exerts trophic eﬀects on the jejunal
mucosa leading to improvements in body weight gain [165].
Similarly, feeding Gln to weaned piglets alleviates growth
depression resulting from Escherichia coli challenge, via the
maintenance of intestinal morphology and function [166].
Three double-blind randomized controlled trials assessed
intestinal permeability using the urinary excretion of lac-
tulose/mannitol ratio to examine whether oral Gln could
improveintestinalbarrierfunctioninmalnourishedchildren
and thereby enhance growth [167–169]( Table 4). Lima et al.
[168] studied 80 malnourished hospitalized children aged 2
to60monthstocompareenteralformulasupplementedwith
Gln (16.2g/d) versus formula supplemented with isomolar
Gly (8.3g/d) or formula alone for 10d. There was a decrease
in the lactulose/mannitol ratio after 10d Gln supplementa-
tion, which was not observed after Gly nor standard non-
supplemented formula. However, the % urinary excretions
of lactulose or mannitol were not aﬀected. Furthermore, the
mean duration of diarrhea, weight gain, or weight-for-age
z-scores did not diﬀer among groups; however, there was a
trend for weight to increase in children supplemented with
Gln or Gly, compared to nonsupplemented diet. Although
the study compared Gln-supplemented formula to Gly-
supplemented and a nonsupplemented formula, allocation
to the nonsupplemented group was not randomized, and
these children were studied 2y prior to the randomized trial.
Moreover, in the supplemented groups, the Gln and Gly con-
s u m e dp e rdc o n t a i n e dd i ﬀerent amounts of nitrogen, 3.1g
and 1.6g, respectively. Thus, the eﬀect of Gln (independent
of the amount of nitrogen) cannot be conﬁrmed.
A subsequent trial by the same group [169] also demon-
s t r a t e di m p r o v e db a r r i e rf u n c t i o n ,m e a s u r e db yd e c r e a s e d
% urinary lactulose excretion in 107 children (7.9 to 82.2
months of age) administered oral alanyl-Gln (24g/d) for
10d, but not with isonitrogenous Gly (25g/d). However,
alanyl-Gln also led to a reduction in % urinary excretion
of mannitol after 10d, resulting in no change in the
lactulose/mannitol ratio and no diﬀerence between groups.
Interestingly, alanyl-Gln led to improvements in cumulative
change over 120d of weight-for-age and weight-for-height
z-scores (but not height for age). Although it appears that
oral alanyl-Gln supplement may improve intestinal barrier
function and reduce wasting in malnourished children,
absorptive epithelium is also reduced as determined by
a decrease in mannitol recovery. The decreased urinary
excretion of mannitol could be related to the high dosage
used in this study (∼1.79g Gln/kg/d). This study [169]a n d
the previous [168], however, may have been underpowered
to detect an improvement in diarrheal disease morbidity,
which was a secondary parameter (not used in the sample
size calculation). Moreover, a longer supplemental period
was likely necessary to demonstrate signiﬁcant eﬀects.
Finally, whereas this subsequent trial used an isonitrogenous
comparison group, the potential intestinal trophic eﬀect
of Gly limits its use as a control for Gln [6, 170]. This
is also supported by experimental data showing that ORS
containing Gln is equivalent to Gly in enhancing mucosal
regeneration or maintaining hydration status in calves with
viral-induced diarrhea [171].
Williams et al. [167] used a longer supplemental period
of oral Gln (0.5g/kg/d) in 93 malnourished Gambian
infants (aged 4 to 11 months) during the 5-6 month
rainy season but failed to demonstrate improvements in
growth, intestinal barrier function, or plasma markers of
immunostimulation compared to an isonitrogenous control.
Growth was poor and was reﬂected by reductions in weight-
for-age,height-for-agez-scores,andmid-upper-armcircum-
ference during the 5-month supplemental period with no
diﬀerence between groups. Furthermore, supplementation
with either Gln or isonitrogenous amino acids did not
improve lactulose/mannitol ratios or % recovery of lactulose
or mannitol. Plasma immunoglobulin (Ig) concentrations
(IgA and IgG) increased during the study, whereas IgM,
albumin, antichymotrypsin, and C-reactive protein showed
no change. Moreover, morbidity or plasma markers of
immunostimulation were not aﬀected by Gln. The lack of
signiﬁcant eﬀect could have been due to the possible trophic
eﬀects on the intestine of nitrogen or amino acids (e.g.,
Gly, Glu, and Cys) in the control group [6, 170], which
consisted of a mix of nonessential amino acids. Alternatively,
the constant daily exposure of these infants to pathogens
or the possible inﬂuence of underlying diseases may have
prevented any improvement with Gln. Finally, infants may
n o th a v eb e e nt r u l yG l nd e ﬁ c i e n ta ss o m er e c e i v e dG l nf r o m
breast milk or other dietary sources. However, food intake
data (breastfeeding in particular) was lacking.
Although apparently safe and well tolerated, results from
double-blind randomized controlled trials are conﬂicting
regarding the eﬃcacy of oral Gln in the treatment of
diarrheal disease [160–162, 168] or in enhancing intestinal
barrier function [167–169]o rg r o w t h[ 167–169] in children
suﬀering from diarrhea or malnutrition. Furthermore, any
beneﬁcial eﬀect of oral Gln does not seem to result from a
modulation of the immune response [161, 167].
Large randomized controlled trials are needed with
adequate power, treatment durations, and objective outcome
measures. Also because speciﬁc subgroups of infants and
children may or may not respond to supplemental Gln,
patient selection criteria should be clearly deﬁned, particu-
larly with respect to diarrheal disease severity (e.g., secretory
diarrhea), hydration status (e.g., severely dehydrated), or
age (e.g., infants ≥ 12mo). The choice of control (e.g.,
isonitrogenous) is also an important issue in the design of
these studies due to a potential intestinal trophic eﬀect of
otheraminoacids,suchasGly[6,170].Finally,consideration
should be given to the possible inﬂuence of factors, such as
underlying disease, complications, or systemic infections as
well as food intake (particularly breastfeeding in infants).J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 23
3.5. Glutamine Supplementation in Pediatric Oncology Pa-
tients. Some studies in adult cancer patients indicate ben-
eﬁcial eﬀects of Gln supplementation after chemotherapy-
radiotherapyorbonemarrowtransplant(BMT)[172].Inthe
rat model of methotrexate-induced injury, speciﬁc nutrients
(such as Gln) and growth factors provide protection against
gastrointestinal damage and weight loss [173]. However,
data are limited on the eﬀects of Gln supplementation
in pediatric oncology patients. An initial case report in a
child receiving chemotherapy showed decreased costs and
good tolerance with Gln-supplemented tube feedings [174].
Subsequently, Pietsch et al. [175] assessed the feasibility
of administering Gln-enriched nasogastric enteral feedings
for ∼12.7d in 17 children (aged 2–19y) receiving intensive
chemotherapy or BMT and reported minimal complications
and reduced hospital costs versus PN (Table 5). Ward et
al. [176] conducted a pharmacokinetic dose-ﬁnding study
in 13 pediatric oncology patients (aged 3–18y) undergoing
chemotherapy and concluded that oral Gln at a single dose
up to 0.65g/kg was well tolerated and safe to use in a clinical
study in pediatric oncology patients. However, it was not
feasible to assess the dose-limiting toxicity at higher doses.
Apart from these preliminary studies and a case-control
study that examined parenteral Gln [177], all other trials in
children undergoing treatment for cancer tested oral Gln at
ad a i l yd o s eo f4 g / m 2 body surface area (BSA) [178–181]
(Table 5).
3.5.1. Glutamine Supplementation on Oral Mucositis in Chil-
dren Undergoing Chemotherapy or Bone Marrow Transplant/
Hematopoietic Stem Cell Transplant. Painful oral mucositis
is a common complication after chemotherapy or BMT/
hematopoietic stem cell transplant (HSCT) resulting in
reduced oral intake and frequently requiring PN. In a small
case-control study, Kuskonmaz et al. [177]m a t c h e d2 1
pediatric cases (mean age 8.3 ± 5.2y), who underwent allo-
geneic HSCT and received parenteral Gln supplementation
(0.4g/kg/d) to a group of 20 control children (comparable
with respect to donor type, diagnosis, and age) and observed
a trend toward reduced incidence of mucositis (29 versus
55%, P = 0.118), sinusoidal obstruction syndrome (10
versus 35%, P = 0.067), and drug-related toxicity (14 versus
40%, P = 0.085) (Table 5). Gln supplementation was also
associated with reduced duration of fever (5.7 versus 12.0d,
P = 0.021); however, no diﬀerences in total parenteral nutri-
tion (TPN) use, neutrophil engraftment, Graft Versus Host
Disease, length of stay in hospital, infections, or mortality
were observed.
Three double-blind randomized trials tested the eﬃcacy
of oral Gln compared to Gly placebo in reducing oral
mucositis [178–180]( Table 5). Anderson et al. [179]c o n -
ducted a crossover study whereby 24 patients (16 children
and 8 adults) were randomly assigned to oral Gln over 2
courses of chemotherapy and Gly placebo over another 2
courses (or the reverse order). Supplementation was then
continued for another 14d after chemotherapy. Although
the duration and severity of mucositis was reduced in the
chemotherapy courses in which Gln was provided (4.5d less
with Gln versus placebo, P<0.001), results were based on
patient self-report by means of a calendar completed by the
patients on the duration and severity of mucositis associated
witheachchemotherapycourse.Alsoinadditiontothesmall
sample size, followup of recruited patients was incomplete,
as only 13 patients actually completed at least 2 courses
of identical chemotherapy (10 children aged 4–17y and 3
adults). Hence additional studies with larger numbers were
needed.
These issues were addressed in a larger cohort of 193
patients (including 72 children) undergoing BMT, whereby
the same group assessed mucositis by both self-report and
by opiate use [180]. Patients were prospectively stratiﬁed
by type of transplant (autologous, matched sibling donor
or unrelated donor) and randomized to receive either oral
Gln or Gly placebo during preparative chemotherapy and
radiation until 28d after BMT. In autologous BMT patients,
Gln reduced the severity of oral mucositis assessed by self-
report and by duration of opiate use (Gln: 5.0 ± 6.2d
versus control: 10.3 ± 9.8d, P<0.01). By contrast, in
matched sibling BMT patients, Gln had no eﬀect on self-
report and actually increased the duration of opiate use
(Gln: 23.2 ± 5.7d versus control: 16.3 ± 8.3d, P<0.01),
whereas%survivalatd-28wasincreasedbyGlninallogeneic
patients. Although other outcomes (TPN use, rate of relapse
or progression of malignancy, antibiotic use, graft versus
host disease, d of hospitalization, infections, or survival at
d-100) were not aﬀected, the results suggest that oral Gln
is safe and eﬀective in decreasing the severity and duration
of mucositis in autologous but not allogeneic BMT patients.
The study population was heterogeneous in terms of age
(range: 1–62 years); subgroup analysis, however, of the 72
child participants was not reported.
Aquino et al. [178] further demonstrated the safety and
beneﬁt of oral Gln in reducing the severity of mucositis in
120 children undergoing HSCT. Compared to Gly placebo,
the Gln group showed a trend toward a reduction in the
mean mucositis score (Gln: 3.0 ± 0.3 versus Gly: 3.9 ± 0.4,
P = 0.07) as well as a reduction in the number of d
of IV narcotics use (12.1 ± 1.5d versus Gly: 19.3 ± 2.8d,
P<0.05) and TPN (17.3 ± 1.7dversusGly:27.3 ± 3.6d,
P = 0.01). There were no diﬀerences between groups for the
number of episodes of bacteremia, total number of hospital
d, or mortality. Although consideration should be given to
include oral Gln supplementation as part of the supportive
care of HSCT, the primary endpoint (mean mucositis score)
was subjectively measured by a clinical scoring scale, which
is a limitation of this and other studies that assessed
mucositis severity. Furthermore, the study may have been
underpowered to detect a signiﬁcant diﬀerence, since only
100 mucositis scoring sheets were available for analysis,
whereas the estimated sample size was 120 patients. Finally
the lower incidence of herpes simplex virus-positive children
(a known risk factor for the development of mucositis [178])
intheGlngroupatbaselinemayhaveconfoundedtheresults.
3.5.2. Glutamine on Immune Function: Implications for Chil-
dren with Solid Tumors and Acute Lymphoblastic Leukaemia.
In patients with solid tumors and lowered lymphocyte24 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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proliferative response, Gln treatment may improve immune
function. K¨ ohler et al. [182] studied the inﬂuence of Gln
and glycyl-Gln on the proliferative response of lympho-
cytes isolated from 21 children (aged 1–17y) with solid
tumors, before and after chemotherapy and observed no
diﬀerence in the in vitro lymphocyte proliferation before
or after chemotherapy. Although these in vitro data do not
support the routine use of Gln supplementation to enhance
lymphocyte function in children with solid tumors, speciﬁc
subgroups of tumors showed trends that diﬀered from the
overallﬁndings,butstatisticalpowerwasinadequatetoprove
any diﬀerences.
An in vivo study by Okur et al. [181] examined 21
children (aged 1–17y) with solid tumors to compare the
eﬀects of oral Gln supplementation during a 5-d chemother-
apy course versus another course without Gln and showed
that the immune-enhancing eﬀects of Gln could involve
not only lymphocytes but also the complement pathway
(Table 5). Moreover, Gln supplementation was associated
with signiﬁcant improvements in some nutritional param-
eters and reduced stomatitis severity and antibiotic necessity,
suggesting that oral Gln could be considered in children with
solid tumors receiving chemotherapy.
A recent report in mice has suggested that supplementa-
tion with alanyl-Gln could support the peripheral immune
system and cell-mediated immunity during asparaginase
chemotherapy [183]. This has implications for children
since asparaginase which is used in the treatment of acute
lymphoblastic leukaemia (ALL) (the most common child-
hood cancer) also depletes plasma asparagine and Gln [184,
185]resultinginimmunosuppression.Moreover,lowplasma
concentrations of gluconeogenic amino acids, especially Gln
and Ala have been reported during chemotherapy-related
hypoglycaemia in ALL children [186], which is in contrast
to the increased Gln concentrations observed in the cerebral
spinal ﬂuid of children with ALL undergoing chemotherapy
or with CNS disease [187]. Future animal research is needed
to test the safety and eﬃcacy of Gln during asparaginase
chemotherapy before trials in children with ALL.
Results from 3 randomized trials suggest that oral Gln
supplementation is safe and may reduce the severity and
duration of oral mucositis in patients undergoing treatment
for cancer, including chemotherapy, autologous BMT, and
HSCT [178–180]. Although trials were methodologically
sound, sample sizes were small, and 2 trials included both
pediatric and adult patients. Moreover, outcome (mucositis
severity) was assessed subjectively by the patient rather than
objectively by an independent observer.
The data from nonrandomized preliminary clinical stud-
ies demonstrate safety [176] and suggest that supplemental
Gln may lead to reduced hospital costs in children receiving
chemotherapy or BMT [175], reduced fever duration in
children undergoing HSCT [177], and improvements in
nutritional and immunological parameters in children with
solid tumors receiving chemotherapy [181]. However, in
vitro data do not support the routine use of Gln supplemen-
tation to enhance lymphocyte function in children with solid
tumors [182].
Due to the lack of data in children, additional random-
ized controlled trials are needed with adequate numbers
of pediatric oncology patients to conﬁrm any beneﬁt of
supplemental Gln. Future trials should deﬁne the patient
populations for which Gln may or may not be of beneﬁt,
by using clearly deﬁned selection criteria with respect to
age (e.g., pediatric versus adult), speciﬁc cancer treatments
(e.g., autologous versus allogeneic BMT), or subgroups of
malignancies (e.g., speciﬁc subgroups of solid tumors) and
evaluate eﬃcacy using objective outcome measures that are
both valid and reliable.
3.6. Glutamine in Pediatric Patients with Severe Burns/Trau-
ma. In situations of abnormal muscle protein metabolism
(e.g., severe burns or trauma), endogenous Gln production
could be impaired [188]. Gore and Jahoor [188]o b s e r v e d
decreased arterial Gln concentrations and decreased rates
of Gln turnover, in 5 severely burned children compared
to control children, whereas net eﬄux of Gln did not
diﬀer. Thus, suggesting that reduced plasma Gln, observed
in burned children, results from a deﬁciency in peripheral
Gln production and increased central consumption. This
supports the notion that Gln supplementation may be
needed in pediatric burn patients because of an inadequate
skeletal muscle response.
The reduced plasma Gln concentrations observed after
major burns could also in part contribute to the immuno-
suppression, that is, seen in these patients. An in vitro study
by Ogle et al. [189] isolated neutrophils from 12 pediatric
burn patients (aged 4–18y) at various postburn times to
determine their ability to kill Staphylococcus aureus in the
presence or absence of Gln (20mmol/L) and compared this
with normal subjects. At all but 2 postburn times, Gln
improved the observed abnormal neutrophil bactericidal
function, restoring it to normal levels. Although Gln had
no eﬀect on C3b receptors (CR1) or on phagocytosis, the
restoration of the impaired bactericidal function shown in
this in vitro study provided additional evidence for Gln
supplementation in the diets of pediatric burn patients.
There exists, however, limited clinical data demon-
strating eﬃcacy of supplemental Gln in burn and other
trauma patients (Table 6). Sheridan et al. [190]c o n d u c t e d
the only randomized double-blind trial of supplemental
Gln using a crossover design in 9 pediatric burn patients
(aged 1.3–15.8y) who received in a random order: 48h
of standard enteral feedings (control phase) and 48h of
enteral feedings with Gln (0.6g/kg/d) replacing 20% of
essential and nonessential amino acids. Whole-body protein
kinetics, determined in the fed state at the end of each
study phase, revealed that Leu ﬂux and Leu oxidation were
lower during Gln supplemental period versuscontrolperiod.
However, no signiﬁcant diﬀerences were observed in net
balance of Leu accretion into protein, nitrogen balance, or
plasma Gln concentrations. The lack of beneﬁcial eﬀect on
protein accretion could have resulted from a number of
reasons. Firstly, the use of an isonitrogenous control testsJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 27
Table 6: Glutamine in pediatric patients with severe burns/trauma.
Reference Subjects Design Gln Control Outcomes Results
Sheridan et
al. 2004 [190]
7 pediatric
patients aged
1.3–15.8y with
serious burns
(≥20% of BSA)
tolerating enteral
feedings
Randomized
double-blind
crossover
Enteral Gln; EN
(Pediasure and/or
Jevity) with Gln
(0.6g/kg/d)
replacing 20% of
essential and
nonessential AA
for 48–72h
(n = 7)
Isocaloric
isonitrogenous
standard EN
(Pediasure and/or
Jevity)
supplemented
with modular
protein (Promod)
for 48–72h
(n = 7)
Whole-body
protein kinetics
(IV infusion of
L-[1–13C]Leu,
NaH13CO3) after
48h enteral
feeding (fed
state), nitrogen
balance, plasma
Gln
concentrations
Decreased Leu ﬂux and
Leu oxidation rate, no
diﬀerences in net
balance of Leu
accretion into proteins,
nitrogen balance or
plasma Gln
concentrations, well
tolerated
Chuntrasakul
et al. 2003
[195]
36 trauma
patients aged
15–60y (n = 16
severe trauma;
n = 20 burn BSA
30–60%)
Randomized
controlled
Enteral Gln;
exclusive EN
enriched with
Arg, Gln,
omega-3 fatty
acids (Neomune)
started on
postinjury d-2
until d-10
(≤0.15g/kg/d
Gln) (n = 18)
Standard
exclusive EN for
trauma patients
(traumacal)
started on
postinjury d-2
until d-10
(≤0.07g/kg/d
Gln) (n = 18)
Biochemical and
immune
parameters after
10d
supplementation,
morbidity, and
mortality
No diﬀerences in
immunologic or
biochemical
parameters (except
increased serum total
protein, decreased
serum triglycerides),
no signiﬁcant
diﬀerences in nitrogen
balance, LOS in
ICU/hospital, d to
wean oﬀ ventilator, or
mortality, well
tolerated
Yang and Xu,
2007 [196]
46 patients aged
7–68y with severe
traumatic brain
injury
Randomized
controlled
Enteral or
parenteral Gln;
Gln-Ala dipeptide
(n = 23)
Routine
nutritional
therapy (n = 23)
LOS in
neurosurgical
ICU, mortality,
lymphocyte
count, and related
complications
No signiﬁcant
diﬀerences in
mortality, LOS in
neurosurgical ICU,
lung infection or
alimentary tract
hemorrhage or
lymphocyte count
BSA: body surface area; EN: enteral nutrition; AA: amino acid; IV: intravenous; LOS: length of stay; ICU: intensive care unit.
the speciﬁcity of Gln but also results in a reduction in
both essential and nonessential amino acids in the Gln diet,
which may have counterbalanced any beneﬁcial eﬀect of Gln.
Furthermore, the risk of type II error cannot be ruled out,
since only 7 out of the 9 children enrolled actually completed
the study. Finally, the Gln feeding period may have been too
shorttoreplenishthedepletedGlnpoolsinstressedpediatric
burn patients. Hence, a longer supplemental period may be
required to restore plasma Gln concentrations and stimulate
protein accretion in this population.
Microdialysis and magnetic resonance spectroscopy ob-
servations in children indicate that the Gln/Glu balance
in the injured brain may play a signiﬁcant role in the
pathophysiology of traumatic head injury in children [191–
193]. Moreover, higher brain Glu/Gln ratio correlates with
increased tissue damaging procedures in asphyxiated term
neonates [194]. The eﬃcacy of supplemental Gln in severe
trauma was tested in 2 small trials that included both pedi-
atric and adult patients [195, 196]( Table 6). Yang and Xu
[196]comparedGln-Aladipeptideversusroutinenutritional
therapy in 46 patients aged 7–68y with severe traumatic
brain injury. Chuntrasakul et al. [195]c o m p a r e di m m u n o -
nutrient formula enriched with Gln versus standard EN in
36 patients aged 15–60y with severe burns/trauma. Results
were inconclusive since studies were underpowered to detect
statistically signiﬁcant diﬀerences, particularly for nonspe-
ciﬁc, multifactorial outcomes, such as length of stay and
mortality. Also the clinical heterogeneity (wide age range)
of subjects included limits application to children. Apart
from methodological issues (e.g., incomplete description
of blinding and randomization procedures), the study by
Chuntrasakul et al. [195] used a commercial product that
combined Gln with added Arg and omega-3 fatty acids. As
such, it is diﬃcult to assess the eﬀects of Gln apart from the
eﬀects of other nutrients. Furthermore, the actual intake of
Gln was not signiﬁcantly greater in the study group versus
control (≤0.15 versus ≤0.07g/kg/d, resp.). Thus, any eﬀect
of Gln may have been blunted.
In summary, although in vitro data suggest beneﬁcial
eﬀects of supplemental Gln in pediatric burn patients
[189], clinical data are less encouraging [190]. Short-term
enteral Gln is apparently well tolerated but does not result28 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
in an immediate whole body protein gain in pediatric
burn patients [190]. Moreover, studies showing beneﬁts of
supplemental Gln in pediatric and adult patients with severe
trauma are inconclusive, and methodological problems have
been noted [195, 196]. Larger well-designed studies are
needed, especially in children to test any clinical beneﬁt.
Protein kinetic studies should consider the duration of
administration, for example, testing enteral Gln adminis-
tered over longer periods on protein metabolism as well
as on its own metabolism to determine whether Gln’s
protein-sparing eﬀect also applies to burned children. Such
studies might also consider the route of administration, as
no study has yet tested the eﬃcacy of parenteral Gln on
protein metabolism or on clinical outcome in pediatric burn
patients.
3.7. Enteral Glutamine Supplementation in
Chronic Diseases of Childhood
3.7.1. Enteral Glutamine Supplementation in Children with
Duchenne Muscular Dystrophy. Duchenne muscular dystro-
phy (DMD) is an X-linked disease caused by a defect in the
gene encoding for dystrophin (a cytoskeletal protein) [197].
The absence of dystrophin expression is associated with a
p r o g r e s s i v ea n ds e v e r el o s so fm u s c l em a s sa n df u n c t i o n .
Studies on protein metabolism suggest that muscle wasting
in DMD could result from a reduction in muscle protein
synthesis or an increase in protein degradation or both [198–
200]. Because skeletal muscle is the body’s main producer
and exporter of Gln and muscle mass is drastically reduced
in DMD, the need for Gln may be increased in persons who
have this disease. Furthermore, in DMD as in other protein-
wasting conditions, the intramuscular Gln concentration is
low [201, 202]. And Sharma et al. [202] suggested that
this may be an underlying reason for muscle wasting in
DMD. Additionally, we have demonstrated that compared
to normal boys, the dramatic muscle mass loss observed in
DMDboysaged10ywasassociatedwithadecreaseinwhole-
body Gln availability in the postabsorptive state, resulting
from a decrease in Gln de novo synthesis [203]. Thus, in
DMD as in other catabolic stress conditions, Gln might be
considered a conditionally essential amino acid.
We conducted 2 separate studies using stable isotope
methodology [204, 205]( Table 7), to test the eﬀect of oral
Gln on whole-body protein and Gln metabolism in DMD
children during the postabsorptive state. In the initial study
[204], Leu and Gln kinetics were measured in 6 DMD boys
aged 8–13y on 2 consecutive days while children received
a 5-h oral administration of ﬂavoured water (Kool-Aid)
on the ﬁrst study day followed by Gln (0.6g/kg) dissolved
in the same ﬂavoured water on study day-2. During Gln
administration,LeureleasefromproteinbreakdownandLeu
oxidation rate both decreased by 8% and 35%, respectively
(P<0.01), resulting in no change in nonoxidative Leu
disposal (an index of protein synthesis). Whereas, whole
body Gln exchange in the plasma doubled (P<0.01), Gln
from protein degradation and Gln de novo synthesis both
decreasedduringoralGlnadministration.Thesepreliminary
data suggested that acute oral Gln might have an acute
protein-sparing eﬀect in children with DMD resulting from
a decrease in whole-body protein degradation and Gln de
novosynthesis.However,resultsshouldbetakenwithcaution
due to the small sample size. Additionally, the order of
treatment allocation was not randomized, and participants
and assessors were not blinded to treatment. Moreover, the
speciﬁcity of Gln’s eﬀect on protein metabolism could not
be tested as measurements were not performed using an
isonitrogenous control group as well.
We addressed these shortcomings more recently by
conductingadouble-blindrandomizedcontrolledtrial[205]
in 26 DMD boys (aged 7–15y) to test whether the acute
protein-sparing eﬀect of Gln persisted when oral Gln
(0.5g/kg/d) was given for 10d and whether the eﬀect was
speciﬁc to Gln, by comparing the Gln-supplemented group
to an isonitrogenous control (amino acid mixture). Whereas
plasma Gln concentrations were not altered this time (since
kinetic studies were performed 24h after Gln or amino
acid administration), the 9% (P<0.05) decrease in Leu
release from protein breakdown persisted after 10d Gln
supplementation and endogenous Gln from protein degra-
dation also decreased. Similar eﬀects were observed after
10d amino acid supplementation; however, the magnitude
of the decrease in whole-body proteolysis was less (−4%, P<
0.05). There were no signiﬁcant eﬀects on other estimates
of Leu and Gln turnover or on body composition (fat-
free mass, % fat mass, muscle mass, and weight) after 10d
supplementation in either group. The lack of signiﬁcant
diﬀerence between Gln and isonitrogenous control could be
explained by the variability in disease progression among
the study population, since Gln treatment in DMD may
have diﬀerent eﬀects depending on the stage of the disease
process [206]. It is also possible that a higher dose or longer
treatment duration may be necessary to demonstrate the
speciﬁc eﬀect of Gln, separate from its role of providing
nitrogen. This highlights the need for dose and time course
data on Gln administration in DMD. Alternatively, the
route of administration (enteral versus parenteral) could
partly explain the lack of signiﬁcant diﬀerence, since Gln’s
protein-sparing eﬀect may be less dramatic when it is given
enterally [125, 127] as opposed to parenterally [80, 105], as
demonstratedinstudiesonproteinmetabolisminpremature
infants of LBW [126].
Based on experimental data showing that Gln improved
performance in the mdx mouse model of DMD [207],
Escolar et al. [206] conducted a randomized double-blind
placebo-controlled multicentre study to test the eﬃcacy and
safety of 6-month oral Gln (0.6g/kg/d) in 35 ambulant
steroid na¨ ıve boys with DMD aged 4–10y (Table 7). Whereas
there were no signiﬁcant diﬀerences in the primary outcome
(manual muscle testing score) or on quantitative measure-
ments of muscle strength, subgroup analysis showed that
in younger boys (<7y) the Gln group had signiﬁcantly less
deterioration over 6 months in timed functional tests versus
placebo.Althoughtherewasatrendtowardlessdeterioration
in quantitative and functional measures of muscle strength
with Gln treatment over 6 months, the eﬀect did not reach
signiﬁcance for the cohort as a whole. The inability to detectJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 29
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a signiﬁcant diﬀerence in the primary outcome could be
explained by the unexpected lack of strength deterioration
(measured by manual muscle testing) in the placebo group
over the 6-month trial. Thus, the study may have been
underpowered since power calculations were based on
previous natural history data of DMD [208]. The signiﬁcant
age-related results must be interpreted with caution as they
were based on an unplanned subgroup analyses in a small
group of patients. Larger trials incorporating ap r i o r iage
stratiﬁcation are required to test the disease-modifying eﬀect
of long-term Gln supplementation in DMD.
Our group has recently completed a multicentre ran-
domized controlled crossover trial in 30 prepubertal DMD
boys aged 2–10y to test whether 4-month oral Gln can
slow the progressive loss in muscle mass and function that
occurs in these children [209]. Subjects received 4-month
Gln separated by a 1-month washout, followed by 4-month
placebo (maltodextrin) or vice versa. The order of treatment
allocation was randomized. Overall, there was no apparent
functional beneﬁt as tested by comparing Gln versus placebo
on change in walking speed at 4 months (primary outcome)
or in secondary measures of muscle function (2-minute walk
test,work,andpower). Weobserved nodiﬀerences in muscle
mass (urinary creatinine), markers of protein breakdown
(urinary 3-methyl-histidine/creatinine), or serum creatine
phosphokinase in the Gln group compared with placebo,
except for a blunted increase in fat free mass in the Gln
group which led to a greater increase in fat-mass percentage.
Our ﬁndings that functional measures did not deteriorate
during the 4-month placebo phase or over the course of the
9-month trial were not as expected. Based on natural history
data [208], the trial was powered to detect a 10% diﬀerence
in walking speed after 4-month Gln compared to placebo.
However, we did not consider the greater placebo eﬀect
reported in children [210] which could have narrowed the
expected eﬀect size of Gln treatment. Interestingly, subgroup
analysis revealed a signiﬁcant eﬀect of Gln treatment on
functional measures in boys taking corticosteroids (P<
0.05). Speciﬁcally, boys taking corticosteroids showed a
signiﬁcantdecline inwalkingspeedduringtheplacebophase
(−40%, P<0.05), whereas walking speed remained stable
when corticosteroid-treated boys received Gln treatment for
4 months. Although the ﬁndings must be interpreted with
caution, because they derive from an unplanned analysis
in a small subgroup of boys (n = 5), they might suggest
a rationale for Gln supplementation in conjunction with
corticosteroid therapy which needs investigation.
In summary, studies on protein metabolism in DMD
children suggest a protein-sparing eﬀect of Gln, resulting
from a decrease in whole-body proteolysis [204, 205]. More-
over, we have identiﬁed a potential antioxidant protective
mechanism for Gln’s antiproteolytic eﬀect in dystrophic
muscleofyoungmdxmice[35].Althoughsafe,supplemental
Gln does not appear to improve muscle strength [206]o r
function in DMD children [209]. Better targeting of speciﬁc
subgroups (younger DMD children or DMD children under
stress, e.g., corticosteroid treatment) is necessary to fully
evaluate the presence (or absence) of beneﬁts. Fundamental
research is also needed to elucidate potential mechanisms
whereby therapies such as Gln target events downstream of
the genetic defect in the progressive dystrophic pathology.
3.7.2. Enteral Glutamine Supplementation in Children with
Sickle Cell Anemia. Children with sickle cell anemia often
have decreased height and weight and reduced muscle mass
when compared with healthy children [211, 212]. This may
be partly due to increased metabolism, since prepubertal
children with sickle cell disease have been shown to use
approximately 19% more energy, 58% more protein, and
47% more Gln compared with age-, sex-, and race-matched
controls[213], even in the absence of sickling, vaso-occlusive
disease or intercurrent illness, suggesting that sickle cell
children may have greater protein and energy needs than
healthy children, and this could lead to impaired growth.
The increased protein and energy needs could be due in part
to the increased erythrocyte production as a result of the
chronic hemolysis and anemia that leads to increased cardiac
output[213].Inadultsicklecelldiseasepatients,oralGlnhas
been shown to improve NAD redox potential of sickle red
blood cells and may result in reduced oxidative stress suscep-
tibility [214]. Moreover, low erythrocyte Gln may contribute
to alterations in the erythrocyte redox environment and
may play a role in hemolysis and pulmonary hypertension
in patients with sickle cell disease [215]. As well, reduced
concentrations of plasma Gln have been reported in children
with sickle cell disease [216], malaria [217, 218], and β-
Thalassemia [219], which may be related to the growth
impairment in height and weight also observed in these
children.
Whereas previous data suggest positive physiological
eﬀects of Gln in sickle cell disease [214, 220, 221], Williams
et al. [222] were the only group to have examined the role
of Gln in children who have this disease (Table 7). They
studied 27 children with sickle cell anemia (aged 5.2–17.9y)
andobservedthatoralGln(0.6g/kg/d)administrationfor24
weekswasassociatedwithadecreaseinrestingenergyexpen-
diture and increased body mass index, % fat mass, muscle
strength, and plasma concentrations of Gln compared to
baseline. Subgroup analysis in underweight children showed
an even greater decrease in resting energy expenditure which
was not observed in normal weight sickle cell children.
While it is possible that lowering resting energy expenditure
with supplemental Gln may be an eﬀective way to improve
growth of children with sickle cell disease, the study design
(i.e., lack of control group) underscores the need for large
randomized controlled trials to test this hypothesis. Future
studies should also focus on speciﬁc subgroups of sickle
cell disease children, in whom Gln utilization may exceed
endogenous Gln de novo synthesis or exogenous supply,
resulting in Gln depletion, for example, when sickle cell
disease children suﬀer from acute intercurrent illness or
malnutrition.
3.7.3. Enteral Glutamine Supplementation in Children with
Cystic Fibrosis. Cystic ﬁbrosis in children is often associated
with malnutrition and poor growth. Chronic malnutrition
in combination with frequent infections that are linked with32 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
acute stress may lead to depletion of body Gln stores in cystic
ﬁbrosis. Compared with normal children, neutrophil Gln
deﬁciency has been observed in cystic ﬁbrosis children [223].
Moreover, cystic ﬁbrosis children with severe mutations
showed even lower neutrophil Gln content compared to
thosewithmildmutations[223].BecauseGlnisafreeamino
acid,Darmaunetal.[224,225]hypothesizedthatGlnshould
be readily absorbed in cystic ﬁbrosis children with malab-
sorption secondary to exocrine pancreatic insuﬃciency and
maybe of potential beneﬁt.
In this one trial [225]( Table 7), Leu and Gln kinetics
were measured in the postabsorptive state in 9 prepubertal
(age 9.6 ±0.5y) children with cystic ﬁbrosis who were either
malnourished or short stature to test whether 4 weeks of
oral Gln (0.7g/kg/d), subcutaneous human recombinant
growth hormone (rhGH; 0.3mg/kg/week), or a combination
of both agents (given in a random order) altered protein
and Gln metabolism. Compared to baseline, 4-week oral Gln
increasedplasmaGlnconcentrations,whereasproteinorGln
metabolism was not aﬀected. In contrast, rhGH (as well as
the combination of Gln+rhGH) reduced Leu oxidation and
increased nonoxidative Leu disposal (an index of protein
synthesis) with no change in Leu release from proteolysis.
rhGH did not alter whole-body Gln metabolism (rate of Gln
appearance, Gln release from proteolysis, or Gln de novo
synthesis). Gln or rhGH given individually were associated
with slight increases in lean body mass. Whereas Gln alone
did not alter glucose metabolism, the increase in glucose
and insulin/glucose ratio after rhGH treatment were blunted
when rhGH was combined with oral Gln. Although oral Gln
had no measurable protein anabolic eﬀects in the fasting
state in prepubertal cystic ﬁbrosis children who are either
malnourished or short, it is worth noting that Leu oxidation
decreased in 6 out of 9 patients after Gln supplementation.
Moreover, only 9 patients (of the12 recruited) completed
the study. Hence, in addition to the limited statistical
power, the wide intersubject variability of this heterogeneous
population may have precluded the detection of Gln’s eﬀect.
Data from this one small study is not suﬃcient to
determine whether Gln supplementation provides any ben-
eﬁt in cystic ﬁbrosis children. Further study is needed. In
addition to outcomes such as protein metabolism, glucose
metabolism, and body composition, it may be worthwhile
to test the eﬀect of Gln on other outcomes, for example,
immune function. Future studies should also focus on
speciﬁc subgroups of this heterogeneous population, who
may be Gln deﬁcient, for example, children with severe cystic
ﬁbrosis mutations.
3.7.4. Enteral Glutamine Supplementation in Children with
Type 1 Diabetes. Although Gln is thought to be a major
source of carbon for gluconeogenesis [66], results are con-
ﬂicting on whether Gln impairs or accelerates recovery from
hypoglycaemia [226–228]. A recent randomized crossover
pilot study in children with type 1 diabetes has investigated
whether oral Gln could improve hypoglycaemia during
exercise and overnight after exercise [229]. Ten adolescents
(mean age 15.2 ± 1.4y) on insulin pumps were randomized
to receive a drink containing Gln or placebo preexercise and
at bedtime (0.25g/kg/dose). Blood glucose was monitored
hourly overnight. Fasting plasma Gln and ammonia concen-
trationsweremeasuredthefollowingmorning16hpostexer-
cise. Subjects returned within 3 weeks for an identical study
with the reverse treatment. Blood glucose concentrations
showed a similar % drop from baseline during exercise in
Gln and placebo groups. Although a comparable number
of subjects developed hypoglycaemia during exercise on Gln
or placebo, postexercise overnight hypoglycaemia was more
frequent after Gln than after placebo (≤70mg/dL: Gln, 19%;
placebo, 15%; P<0.05; ≤60mg/dL: Gln, 7.7%; placebo,
3.6%; P<0.05). The cumulative probability of overnight
hypoglycaemia was increased on the Gln day versus the
placebo day (80% versus 50%, P<0.05). Whereas plasma
Gln concentrations were higher than the morning after
Gln administration as compared with placebo (316μmol/L
versus 200μmol/L, P<0.001), plasma ammonia con-
centrations were similar. This pilot data suggests that Gln
supplementation increases the likelihood of postexercise
overnight hypoglycaemia in adolescents with type 1 diabetes.
Results, however, are limited given the small sample size and
lack of direct measurement of insulin sensitivity. Further
study is needed in larger numbers of children with type
1 diabetes to determine whether Gln aﬀects peripheral or
hepatic insulin sensitivity.
4. Conclusions
4.1. Premature Neonates. Although parenteral Gln appears
to have a protein-sparing eﬀect in premature infants of
LBW [80, 105], randomized trials and a meta-analysis of 7
high quality trials cannot conﬁrm any consistent beneﬁt(s)
of enteral or parenteral Gln on clinical outcomes (e.g.,
mortality, length of stay, feeding tolerance, infections/sepsis,
NEC, ventilator use, growth, or neurological sequelae) [99,
100, 102, 107, 111, 113, 129]. Further, the beneﬁcial eﬀects
of parenteral Gln on protein metabolism were not reported
with enteral Gln supplementation [125, 127], likely because
the majority of enteral Gln is used in ﬁrst pass in premature
infants [126]. Although several high quality trials have
studiedtheeﬀectsofenteralandparenteralGlninpremature
neonates, results remain indeterminate. There are a number
of explanations for this. Firstly, the choice of clinically
relevant outcomes (e.g., rare events, like mortality) that are
not inﬂuenced by other factors is challenging in a population
of infants with rapidly changing clinical status. Furthermore,
the diﬀerences in nutritional support regimens; diﬀerent
eﬀects of enteral versus parenteral Gln supplementation
could also contribute to the conﬂicting results. In addition
to the route of administration (enteral versus parenteral),
diﬀerences in Gln dose, supplement duration, studies varied
with respect to initiation, advancement, and tapering of
parenteral amino acids as well as the total daily intake. This
in combination with the diﬀerent practices for introducing
or withholding EN and the variable breast milk intake limits
comparisons between studies and could represent sources
of confounding within a particular study. For example,
advancement of amino acids (and hence Gln) may be
less aggressive in sicker infants, the subgroup that may beJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 33
more likely to beneﬁt from exogenous Gln. Finally, the
heterogeneous study population of premature neonates with
diﬀerent gestational age, birth weight, and varying degrees of
acute illness may also aﬀect outcome.
4.2. Older Infants and Children with Disease. In older infants
and children with disease, fewer high-quality randomized
trials have studied the eﬀects of supplemental Gln in any one
speciﬁc population. In infants with surgical gastrointestinal
disease, data from 2 randomized trials and a meta-analysis
are insuﬃcient to determine whether enteral or parenteral
Gln confers clinically signiﬁcant beneﬁts (feeding tolerance
or intestinal permeability) [130–132]. Apart from this one
trial [131], the eﬀects of parenteral Gln supplementation
have not been studied in older children with disease. In
children suﬀering from diarrhea or malnutrition, results
from 6 randomized trials are conﬂicting regarding the
eﬃcacy of oral Gln in the treatment of diarrheal disease or
in improving intestinal barrier function or growth [160–
162, 167–169]. In pediatric cancer patients undergoing
chemotherapy, autologous BMT, and HSCT, results from
3 randomized trials suggest that oral Gln may reduce
the severity and duration of oral mucositis [178–180].
However, preliminary studies in children with solid tumors
are conﬂicting [181, 182]. Finally in DMD children, oral
Gln inhibits whole-body proteolysis but does not appear to
improve muscle strength or function (based on results from
3 small randomized trials) [205, 206, 209].
Studies in other childhood diseases are limited. In
older children with gastrointestinal disease, ﬁrm conclusions
cannotbemadefrom1smallrandomizedtrialontheeﬃcacy
of enteral Gln on remission rates in pediatric patients with
active Crohn’s disease [148]. Furthermore, there is a lack
of good quality data speciﬁc to pediatric patients with SBS
to suggest any beneﬁt of supplemental Gln in promoting
intestinal adaptation, since studies are limited to case series
[140–142]. Except for 1 small randomized trial in severely
burned children showing no beneﬁcial eﬀects of enteral
Gln on whole-body protein accretion [190], the 2 trials in
pediatric and adult patients with severe burns/trauma had
signiﬁcant methodological limitations (high risk of bias)
[195, 196]. And insuﬃcient evidence is available to confer
any beneﬁcial eﬀect(s) of Gln supplementation in chronic
diseases of childhood. Other than one small randomized
crossover in diabetic adolescents [229], data are limited to
time series studies in cystic ﬁbrosis and sickle cell anemia
[222, 225].
Given the conﬂicting results (e.g., in premature infants)
and insuﬃcient data in other childhood conditions, the rou-
tine use of supplemental Gln cannot be recommended in any
onepediatricpopulationasawhole.Itseemsthatthebeneﬁts
of Gln supplementation are limited to speciﬁc subgroups
of pediatric patients who may suﬀer from Gln deﬁciency,
whereby Gln utilization exceeds the body’s synthetic capacity
or exogenous supply. Although mechanisms of Gln action
have been proposed, there is still a need for fundamental
research to better deﬁne the role of Gln in diﬀerent life
stages of childhood and to determine how Gln modulates
cell-speciﬁc functions during health and disease processes.
AbetterunderstandingofthemechanismsofGlnwillhelpto
eventually identify the subpopulations of pediatric patients
for which Gln may (or may not) be beneﬁcial. Given the
abundant evidence demonstrating safety in all conditions
studied so far, eventual evaluation in speciﬁc subgroups of
children is warranted. However, the methodological issues
noted from previous trials should be seriously considered in
any future large randomized controlled trial involving Gln
supplementation in sick children.
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